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1 Introduction 
 
1.1 Introduction part one – general characteristics of cancer and molecular mechanisms. 
 
1.11 Cancer 
In Western, industrialized countries, cancer is the second most common cause of death, with only 
cardiovascular diseases having a higher percentage of overall mortality. Cancer has severe effects on 
many aspects of a patient’s life, often significantly reducing life expectancy and quality. The 
knowledge of suffering from a life-threatening illness also poses a great psychological challenge, 
sometimes leading to depression, anxiety, fear, and panic attacks. The course of the disease is often 
protracted, prompting social and, eventually, financial problems to arise as the patient’s ability to 
participate in former activities may be impaired. Besides affecting physical and emotional health on 
the individual basis, the frequency of cancer, in line with the high cost of current therapies, also 
poses a challenge to a nation’s healthcare system.  Since there is a clear correlation between age and 
the incidence of cancer, the rising life expectancy is expected to lead to a worldwide increase in the 
incidence of cancer and cancer-related deaths. Additionally, the mortality from cardiovascular 
diseases has decreased significantly faster than the mortality from malignancies in the last decades. 
If the current trends continue, cancer will become the primary cause of death in industrialized 
countries within the next 15 to 20 years (RKI 2013). 
Therefore, research regarding the causes, the evolution, the behaviour and the therapy of the 
different entities of cancer is of great importance to many current and future patients, as well as the 
society in general. Since Johannes Peter Müller showed that cancer tissue is composed of cells, 
similar to normal tissue in 1850, the scientific development has accelerated. New technologies have 
been generating new insights with increasing frequency over the past 160 years. Of this multitude of 
discoveries, it may have been Theodor Boveri’s observation of chromosomal aberrations in cancer 
cells in 1914, and Peter Nowel’s and David Hungerford’s discovery of the Philadelphia chromosome 
in 1960, which created an awareness towards the role of chromosomal abnormalities in the 
malignant transformation of cells. It was in 1972, along with the introduction of new chromosome 
banding techniques, that Janet Rowley was able to demonstrate that the Philadelphia chromosome 
was the result of a translocation between chromosome 9 and 22. In 1983, it was discovered that this 
translocation led to the fusion of the 5’ part of the BCR gene and the 3’ part of the ABL1 gene, 
marking the first description of an oncogenic fusion gene (Heisterkamp et al., 1983). Since then, an 
increasing number of such fusions have been described. The functional characterization of the 
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proteins originating from these fusion genes has greatly contributed to the understanding of the 
pathology of the malignant transformation on the cellular, as well as on the molecular level. During 
the last decade, these proteins have become preferred targets for the development of new 
treatments, with the first clinical trial of a BCR-Abl kinase-inhibitor, Imatinib, being conducted in 
1998. 
 
1.12 Alterations of the genome and cancer 
A wide variety of findings support the assumption that cancer is caused by alterations of the genome. 
Firstly, the clonal nature of malignant cells strongly suggests that they are derived from one origin, a 
single cell, which underwent a malignant transformation. Secondly, a strong correlation between the 
onset of cancer and the presence of substances causing DNA damage has been observed. 
Throughout the life of a cell, its DNA is subjected to a multitude of endogenous and exogenous 
hazards, such as reactive oxygen species or ultraviolet radiation. But it is also believed that many 
mutations occur as a consequence of normal DNA metabolism like DNA transcription and replication. 
While the extent of the damage may vary from a single base substitution to chromosomal 
aberrations, such as balanced or imbalanced translocations or even aneuploidy, the resulting 
phenotype will usually be determined by the genes which are involved. 
Usually, the DNA damage recognition and repair mechanisms of a mammalian cell are extremely 
effective. In vivo DNA replication has an error rate of roughly 1 in 10⁹ base pairs, a figure which is 
many times lower than the error rate a purely thermodynamic model would suggest (Wagner C, 
Müller O., 2010). While minor damages like single base mutations or single- and double-strand 
breaks can be repaired, more extensive damage, especially on a chromosomal scale, will most likely 
lead to apoptosis. Even if a mutation remains undetected, its chances of yielding a tumorigenic effect 
are relatively slim. Often, introns or noncoding regions will be affected and in other instances, the 
mutation of non-essential genes will leave the cell functional. However, if a mutation occurs within or 
in the vicinity of a proto oncogene or tumour suppressor gene, the consequences can be profound. 
This may result in a gain of function (GOF) or a loss of function (LOF) of the gene, triggering what 
could be the first step towards the creation of a cancer cell. 
It is believed that, in most cases, several events within a single cell are required for the development 
of cancer. According to this model, an initial mutation may impair the ability to control DNA damage 
or to initiate apoptosis, leaving the cell more vulnerable to further mutations. The result is a lineage 
of cells undergoing what is called a somatic evolution involving the activation of oncogenes and the 
deactivation of tumour suppressor genes. During this process, the biological properties of the cell will 
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change, such as the disappearance of senescence and apoptosis or the acquisition of the capacity to 
induce angiogenesis. Also, the dependence on external growth factors will be reduced or even 
disappear completely. 
 
1.13 The cell cycle 
The common characteristic of all known types of cancer is the uncontrolled growth of pathological 
tissue, caused by an imbalance between mitosis and apoptosis. Simply put, the portion of 
proliferating cells in cancer tissue is greater than it is in healthy differentiated adult tissue. A large 
part of the various mutations within a cell’s genome, which have been identified as promoting 
malignant transformation, are directly or indirectly linked to cell cycle control. Therefore, the 
understanding of the cell cycle is crucial to understanding the pathological changes within the cancer 
cell. 
In preparation of mitosis, a cell will go through the interphase, which can be divided into 3 parts: The 
G1, S and G2 phase. During the G1, or growth phase, the cell will synthesize mRNA and proteins 
needed for DNA replication, while the number of mitochondria will rise, indicating an increase in 
metabolic activity. The S phase or synthesis phase, is characterized by the replication of the cell’s 
genomic DNA. During G2, the cell will continue to grow while a final checkpoint will ensure its 
readiness to enter the mitotic phase. Finally, the mitotic or M phase is the process of cell division: 
The nuclear DNA will be condensed to form the chromosomes and the nuclear membrane will 
disintegrate. Afterwards, the chromosomes will align at the metaphase plate, to be then separated, 
pulled apart by the shortening microtubules of the spindle apparatus. A new nuclear membrane will 
form around the two sets of chromosomes and the process of cytokinesis, the division of the cellular 
body, will commence until two daughter cells have been formed. After the successful completion of 
mitosis, the daughter cells will either repeat the cycle by entering the G1 phase, or enter the G0 phase, 
a quiescent stage, which is the state of most differentiated cells. Despite the fact that the cell cycle 
machinery is dismantled in G0, these cells still carry the potential to enter the cell cycle again, should 
the opportunity arise. However, some terminally differentiated cells remain in the quiescent GT state 
for the remainder of their existence, which can range from 5 to 6 days in the case of neutrophil 
granulocytes, to an entire human lifespan in the case of neurons. 
Several checkpoints, which depend on control proteins such as cyclins, cyclin-dependent kinases 
(CDKs) and adaptor proteins, regulate the proper and orderly progression through the cell cycle. 
Often triggered by DNA damage, their primary function is to either arrest the cell cycle to allow the 
damage to be repaired, or to initiate cellular apoptosis if the damage proves to be irreparable. Other 
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checkpoints include the G1 checkpoint, or restriction point, which will only permit the cell to enter 
the S phase if extracellular growth factors are present, and the metaphase checkpoint, which will 
inhibit the separation of the daughter chromosomes as long as their kinetochores are not properly 
attached to the spindle fibres. Despite such control mechanisms, the highly complex process of 
mitosis is vulnerable to error, which will sometimes result in mutations or the occurrence of 
chromosomal aberrations in the next generation of cells (Alberts et al., 2002; Lodish et al., 2012). 
 
1.14 Tyrosine kinases 
It is no coincidence that protein kinases constitute the largest proportion within the heterogeneous 
group of oncoproteins. Many external factors promoting cell proliferation will do so by making use of 
a signalling pathway which includes protein kinases attached to a transmembrane receptor. These 
kinases, once activated, will phosphorylate cytoplasmatic proteins such as transcription factors. In 
turn, the phosphorylated transcription factor will be able to travel inside the nucleus to alter the 
expression of certain genes, representing a simple signalling pathway. There are two main groups of 
kinases, the serine/threonine kinases and the tyrosine kinases. I will focus on the mechanisms 
associated with cytoplasmatic tyrosine kinases.  
Non-receptor tyrosine kinases are enzymes which do not have an extracellular or transmembrane 
domain. Therefore, the kinases are located in the cytoplasm or, in some cases, inside the nucleus. 
The enzymes vary in function and purpose. Often activating the cellular pathways of extracellular 
signals, others will promote cell migration or adhesion (In the case of the SRC family) (Wagner C, 
Müller O., 2010). Notable tumour-associated tyrosine kinases are the ABL1 kinase and the families of 
CSK- SRC- and Janus kinases (JAKs). 
In the case of the ABL kinase, an involvement in the processes of cell differentiation, proliferation, 
adhesion and stress response (NCBI Gene, 2014) has been described. Apart from its physiological 
functions, ABL is more commonly known for being a part of the BCR/ABL fusion gene, which is 
associated with malignancies of the bone marrow such as CML and ALL. While the ABL and BCR 
moieties of the fusion protein may vary in size, the fusion protein will always include the coiled-coil 
dimerisation domain of BCR and the kinase domain of ABL. This arrangement allows the dimerisation 
of the ABL kinase, leading to cross-phosphorylation and subsequent activation of the kinase activity 
(McWhirter et al., 1993). In the case of Janus kinases, a family of receptor-associated tyrosine kinases, 
a similar mechanism has been proposed by Griesinger et al. (Griesinger et al., 2005). Usually 
activated by the dimerisation of cytokine receptors, a BCR/JAK2 fusion may yield a similar effect 
through dimerisation of the fusion protein via the coiled-coil domain of BCR. In recent years, JAKs 
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have been best known for their involvement in the JAK/STAT pathway, which has been shown to be 
over-activated in different haematological diseases such as leukaemia, myelofibrosis and 
polycythaemia vera (Baxter et al., 2005; Kralovics et al., 2005). 
 
1.141 Tyrosine kinases and the cell cycle 
The JAK/STAT pathway has a number of genomic targets, such as MYC and CCND2. The protein 
encoded by the latter gene, cyclin D2, is known to bind and thereby activate the cyclin-dependent 
kinases 4 and 6. These CDKs are both active during the G₁ phase, facilitating the entry into the cell 
cycle (de Alboran et al., 2001). Additionally, the cyclin D-CDK4/6 complexes, together with a cyclin E-
CDK2 complex will promote the G₁/S phase transition. The whole process is regulated by extracellular 
growth factors binding to transmembrane receptors, which then activate specific JAKs. Simply put, 
the growth factors are inducing the entry into the cell cycle, and therefore cell proliferation, by 
triggering the JAK/STAT pathway.  
MYC forms homodimers and also heterodimers with MAX, which function as transcriptional 
activators or transcriptional repressors for many different genes. Regarding the cell cycle, MYC 
upregulates the expression of CCND2 and CDK4 promoting cell cycle progression. In addition to 
supporting other vital functions (the inactivation of MYC will cause embryonic lethality in mice), the 
wild type MYC gene has been shown to induce the proliferation of murine B cells in vitro (de Alboran 
et al., 2001). 
 
1.142 JAK/STAT pathways 
JAKs are known to be involved in the transduction of signals from type 1 cytokine receptors, including 
the receptors for IL-2, IL-3, IL-5, IL-6, IL-7 and GM-CSF, and type 2 cytokine receptors including the 
receptors for IFNα, IFNβ, IFNγ and IL-10 and the receptors of growth hormone, prolactin, 
erythropoietin and thrombopoietin (Universal Protein Resource (UniProt)).  The family of Janus 
tyrosine kinases consists of 4 proteins, JAK1, JAK2, JAK3 and TYK, each associated with certain 
cytokine receptors. After binding to these receptors, the Janus kinases activate downstream 
pathways via phosphorylation of cytosolic proteins, as soon as the receptor itself has been activated. 
In turn, STATs bind the cytosolic domain of a specific cytokine receptor, ensuring that only the 
receptor-specific STATs will be phosphorylated. The specificity is achieved by the SH2 (Src-homology 
2) domain of the STAT protein, which binds to a certain phosphotyrosine of the cytosolic domain of 
the receptor. For example, STAT5 is specific to the EPO- and IL-2 receptors, while STAT1 will be 
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activated by the IFNα- and IFNγ receptors. The following table contains an overview of the different 
cytokines, receptor-associated kinases and the associated STAT proteins (Wagner C, Müller O., 2010). 
Interleukin, Interferon Kinase STAT Protein 
IFNα TYK2, JAK1 STAT1, STAT2 
IFNγ JAK1, JAK2 STAT1 
IL-6, IL-10, GM-CSF JAK1, JAK2, TYK2 STAT3 
IL-12 JAK2, TYK2 STAT4 
IL-2 JAK1, JAK3 STAT5 
EPO JAK2 STAT5 
IL-4 JAK1, JAK3 STAT6 
Tab1: Cytokines and receptor-specific STAT proteins. Source: Wagner C, Müller O. Molekulare Onkologie - 
Entstehung, Progression, Klinische Aspekte, 3. Auflage. Georg Thieme Verlag 2010. 
The genes regulated by each STAT differ, depending on the tissue-specific epigenetic modifications. 
STAT5, for example, will act as a transcription factor for genes encoding for milk proteins in the 
mammary gland, while upregulating the expression of the anti-apoptotic Bcl-xl gene in erythroid 
progenitor cells (Lodish et al., 2012). 
 
1.143 Tyrosine kinase inhibitors 
A tyrosine kinase inhibitor, Imatinib (marketed as Gleevec by Novartis), was the first cancer drug 
specifically designed for a distinct molecular target, the BCR/ABL fusion protein in patients with 
chronic myeloid leukaemia (CML). With clinical trials beginning in 1998, the therapeutic results were 
impressive, prompting the development of further kinase inhibitors and leading the way for several 
other targeted therapies in the field of oncology. The target of Imatinib is the ATP binding domain of 
the ABL kinase. By binding in the vicinity of the ATP-binding site, Imatinib locks the active site in a 
closed conformation, thereby inhibiting the ABL kinase activity semi-competitively (Wagner C, Müller 
O., 2010). However, resistances to Imatinib have been observed, especially in later stages of CML. 
Mutations of the ATP binding domain or amplification of the BCR/ABL fusion gene have both been 
described as the cause of resistance to Imatinib (Azam et al., 2003). Newer, so-called second 
generation inhibitors of ABL like dasatinib or nilotinib, which have a much higher affinity (as much as 
300 times) towards the target structure, are currently used in cases of Imatinib resistant CML, with 
significant, but rather limited success (Kantarjian et al., 2006). 
Apart from kinase inhibitors targeting the BCR/ABL protein, additional molecular targets for the 
treatment of various diseases have been identified. Other tyrosine kinase inhibitors include erlotinib 
and gefitinib, targeting the epidermal growth factor (EGF) receptor in the treatment of non-small cell 
lung cancer (NSCLC) and pancreatic cancer and lapatinib, targeting the erbB2 (HER2/neu) epidermal 
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growth factor receptor in breast cancer (Wagner C, Müller O., 2010). Table 2 contains a compilation 
of some tyrosine kinase inhibitors currently in use. 
Inhibitor Target Indication 
Dasatinib ABL  CML, BCR/ABL positive ALL 
Erlotinib EGF receptor NSCLC, pancreatic cancer 
Gefitinib EGF receptor NSCLC 
Imatinib ABL, ARG, Kit, PDGFRα/β CML, BCR/ABL positive ALL, GIST 
Lapatinib erbB2 HER2/neu-positive breast cancer 
Nilotinib ABL, ARG, Kit, PDGFRα/β CML 
Ruxolitinib JAK1/2 Myelofibrosis, polycythaemia vera, plaque psoriasis 
Tofacitinib JAK3 and others Rheumatoid arthritis 
Table 2: A selection of tyrosine kinase inhibitors in clinical use. Source: Wagner C, Müller O. Molekulare 
Onkologie - Entstehung, Progression, Klinische Aspekte, 3. Auflage. Georg Thieme Verlag 2010. 
Ruxolitinib, an inhibitor of the Janus kinases 1 and 2, gained FDA approval in 2011 for the treatment 
of myelofibrosis. During drug development, cell lines containing a mutant, activated JAK2 were found 
to be responsive to ruxolitinib. In cells treated with the substance, a reduction of phosphorylated 
JAK2 and STAT5 proteins was observed, indicating an inhibitory effect on the JAK/STAT pathway. 
During clinical trials involving patients with myelofibrosis, the group receiving ruxolitinib had a 
significant advantage in terms of survival and symptom control, as the drug was shown to reduce 
splenomegaly and anaemia (Harrison C, Vannucchi AM., 2012). Other inhibitors of JAK kinases have 
recently been developed or are still under development. Tofacitinib, originally designed as an 
inhibitor of JAK3, has demonstrated clinical efficiency in the treatment of rheumatoid arthritis. It was 
found to have an inhibitory effect on the cytokine-mediated phosphorylation of STAT1, STAT3 and 
STAT5, blocking JAK/STAT pathways downstream of the JAK-dependent cytokine receptor. In line 
with these findings, the production of inflammatory mediators was found to be significantly reduced 
(Ghoreschi et al., 2011). 
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1.2 Introduction part two – Chronic myeloid leukaemia and a case report from 2005. 
 
1.21 Leukaemia 
Leukaemia, which derives from the Greek words for “white blood”, is a malignant disease of the bone 
marrow, characterized by the autonomous proliferation of a single lymphatic or myeloid cell clone. 
The name leukaemia was introduced by Rudolf Virchow in 1847, in order to describe the unusually 
thick layer of white blood cells, which could be observed above the erythrocyte fraction after 
centrifugation of a patient’s blood sample. The clonal expansion of a malignant cell within the bone 
marrow leads to the displacement of normal haematopoietic tissue into extramedullar organs, 
especially the spleen and liver. In later stages, the accumulation of leukaemic cells within the blood 
will promote clotting as well as the displacement of normal bone marrow will lead to anaemia, 
immunodeficiency and excessive bleeding (Herold, 2013). Leukaemia can be divided into two large 
diagnostic groups, acute and chronic leukaemia. Each of these groups can be further subdivided into 
myelogenous and lymphocytic leukaemia, with a total of four subgroups emerging: Acute 
lymphoblastic and acute myelogenous leukaemia (ALL and AML) and chronic lymphoblastic and 
chronic myelogenous leukaemia (CLL and CML). Each group in turn contains several subtypes, 
differentiated by cytology, clinical characteristics or specific genetic aberrations, with distinct 
therapeutic regimen and different prognoses. 
A graph portraying the relationship between age and incidence for all types of leukaemia will have an 
initial peak during childhood and a steady decline towards the age 25, followed by a prolonged 
plateau of relatively low risk and finally a steady increase of incidence above the age of 50. While ALL 
is the most common type of leukaemia in early life, the chronic leukaemia forms become more 
frequent in higher age. Although ALL is more common during childhood, AML becomes the most 
frequent type of acute leukaemia in adults.  
 
1.22 Chronic myelogenous leukaemia 
Chronic myelogenous leukaemia is the most common chronic myeloproliferative disorder, 
characterized by high numbers of mature neutrophil granulocytes and granulocytic precursors in the 
peripheral blood. It usually occurs in elderly patients, with a slight predilection of males (Alison, 
2007). The disease can be divided into three phases – a chronic, relatively stable phase of variable 
duration, which often yields few symptoms, followed by a symptomatic acceleration phase in which 
an increasing number of myeloblasts and basophils can be observed as the disease undergoes a 
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cytogenetic evolution acquiring additional genomic alterations. The final, mostly lethal stage known 
as blast crisis will see high numbers of blasts flooding the peripheral blood and bone marrow, even 
accumulating in extramedullar locations such as the skin. The prognosis depends heavily on the 
genetic characteristics of the malignancy, with an overall survival of five to ten years. The 
t(9;22)(q34;q11) translocation is a frequent observation, forming the well-known Philadelphia 
chromosome. The translocation, which is present in roughly 85% of cases, usually leads to the 
formation of the BCR/ABL fusion gene, which encodes for a protein containing the coiled-coil 
dimerisation domain of BCR and the kinase domain of ABL (Heim S, Mitelman F., 2009). The high 
tyrosine kinase activity of the fusion protein is regarded to be both bad, since it is the driving force 
behind the development and acceleration of the disease, and beneficial, since its vulnerability to 
tyrosine kinase inhibitors can be exploited. A publication in 2006 by Druker et al. showed that 70 to 
90% of the patients receiving Imatinib displayed a complete cytogenetic response after 60 months, 
with an overall survival rate of 89%, which illustrates the effectiveness of TKI treatment in CML 
(Druker et al., 2006). 
Besides the iconic Philadelphia chromosome, additional chromosomal aberrations, like a loss of the Y 
chromosome, trisomy 8, i(17q), or a second Ph chromosome can be detected during progression into 
the accelerated phase or blast crisis. These additional changes can be found during the accelerated 
and blast crisis phase of 60-80% of the cases. Their presence at the time of diagnosis is a negative 
prognostic factor (Sokal et al., 1988). During the cytogenetic evolution, a great number of other 
rearrangements involving all chromosomes are known to occur, sometimes even related to the 
treatment the patient receives, but their prognostic and therapeutic implications have yet to be fully 
understood. 
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1.23 Atypical CML – a case report by Griesinger et al. 
In 2005, a 63-year-old female patient presented to the outpatient clinic of Braunschweig Hospital 
with fatigue and left upper abdominal pain. Initial blood tests showed several abnormalities, 
including anaemia, leukocytosis and a left shift in the differential blood count. Table 3 contains the 
abnormal parameters found at the time of her first visit at Braunschweig Hospital.  
Parameter Reference Patient 
Metabolic panel   
LDH (U/l) <250 478 ↑ 
Blood count   
Hb (g/dl) 12-16 10.4 ↓ 
Leukocytes (/μl) 3.800 – 10.500 42.000 ↑ 
Platelets (/μl) 140.000-345.000 250.000 
Differential blood count   
Immature neutrophil granulocytes (%) 0-5 11 ↑ 
Segmented granulocytes (%) 30-80 58 
Eosiniphils (%) 0-6 7 ↑ 
Basophils (%) 0-2 3 ↑ 
Lymphocytes (%) 15-50 14 ↓ 
Monocytes (%) 1-12 3 
Additional tests   
LAP (leukocyte alkaline phosphatase) (Index points)  10-110 4 ↓ 
Table 3: Blood test results of the 63-year-old patient. Source: Griesinger F, Hennig H, Hillmer F, Podleschny M, 
Steffens R, Pies A, Wörmann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the result of a 
t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.Genes 
Chromosomes Cancer. 2005 Nov;44(3):329-33. 
A bone marrow examination was performed, revealing hyperplastic bone marrow, a left-shifted 
myelopoiesis and eosinophilia. The blast count was less than 5% and megakaryopoiesis was 
increased. The megakaryocytes where described as discretely dysplastic. A trephine biopsy 
confirmed these findings and, additionally, bone marrow fibrosis was observed. Based on these 
results, the diagnosis of CML was made. The patient was initially treated with hydroxyurea and 
interferon alpha, and a complete hematologic response was achieved. A blast crisis was diagnosed 20 
months after the first diagnosis and in response, the patient was treated with Imatinib for eight 
weeks. However, as it became apparent that the disease was not responding to Imatinib, the patient 
was administered high-dose Ara-C and mitoxantrone. Despite these efforts, the patient died in 
myeloid blast crisis, 24 months after the initial diagnosis of CML (Griesinger et al., 2005). 
At the time of diagnosis, conventional cytogenetics where performed. The outcome was unexpected, 
as it did not show the CML typical t(9;22)(q34;q11.2), but instead a t(9;22)(p24;q11.2) in 21 of 21 
metaphase cells. It was the sole chromosomal aberration at the time. Conventional cytogenetics was 
performed again at the time of the blast crisis, revealing cytogenetic evolution with a 7q deletion 
[del(7)(q22q36)] in 21, and an additional trisomy 19 in five metaphase cells.  A fluorescence in situ 
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hybridization (FISH) using a BCR and an ABL gene probe was performed to analyze the unknown 
(9;22)(p24;q11.2) translocation. Three signals where observed with the BCR probe, but only two 
signals for the ABL probe. These results ruled out any variant of a hidden BCR/ABL translocation, 
indicating that BCR had a novel, yet undetermined fusion partner. 
The JAK2 gene is located on 9p24, and therefore a fusion between BCR and JAK2 seemed to be quite 
likely. To confirm this hypothesis, a RT-PCR assay was performed, using a 5’ sense BCR and a 3’ 
antisense JAK2 primer. The primers where: 
5’ BCR sense primer: 5’-CAG AAC TCG CAA CAG TCC-3’ (bp 1602 – 1622) 
 
3’ JAK2 antisense primer: 5’-TC ATA CCG GCA CAT CTC CAC AC-3’ (bp 3100 – 3081) 
 
Gel-purification and sequencing of the PCR product showed an in-frame fusion between exon 1 of 
BCR and exon 19 of JAK2. An amplification product or roughly 300 bp, spanning the BCR/JAK2 
breakpoint region, could be seen in gel electrophoresis. Based on the sequence, a BCR/JAK2 fusion 
protein of 747 amino acids in length, incorporating the coiled-coil dimerisation (CC) domain of BCR 
and the kinase (JH1) domain of JAK2 was proposed. Fig. 1 shows a diagram of the BCR and JAK2 
proteins and fusion protein as published by Griesinger et al. 
 
Figure 1: The BCR and JAK2 proteins and the proposed BCR/JAK2 fusion protein. Source: Griesinger F, Hennig H, 
Hillmer F, Podleschny M, Steffens R, Pies A, Wörmann B, Haase D, Bohlander SK. A BCR-JAK2 fusion gene as the 
result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.Genes 
Chromosomes Cancer. 2005 Nov;44(3):329-33. 
It is worth noting that the breakpoint of BCR, as described by Griesinger et al., is identical to the 
breakpoint in the BCR/ABL variant leading to the p190 BCR/ABL fusion protein which is common in 
ALL and infrequently observed in CML.  
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1.24 Case reports of BCR/JAK2 fusions 
Case reports of different malignancies of the bone marrow, exhibiting a t(9;22) translocation, but 
without any sign of a BCR/ABL fusion protein, have occasionally been published in the recent years. A 
total of nine cases have been reported worldwide. This involved cases of myeloproliferative disease 
(MD), ALL, AML and CML (Griesinger et al., 2005; Cirmena et al., 2008; Lane et al., 2008; Tirado et al., 
2010; Impera et al., 2011; Elnaggar et al., 2012;Cuesta-Domínguez et al., 2012, Bellesso et al., 2013, 
Schwaab et al., 2014). The publication by Cirmena et al. contains the case report of a 67-year old 
female patient with AML M1 with the a t(9;22)(p24;q11) as the only cytogenetic abnormality at the 
time of diagnosis. This time, the breakpoint of BCR was identical to the breakpoint of the BCR/ABL 
p210 variant. Sequencing revealed that the BCR gene was truncated in exon 14, followed by a 17 bp 
insertion of unknown origin and the 3’ rest of JAK2 beginning with the first nucleotide of exon 11. 
Despite intensive treatment including high-dose chemotherapy and allogeneic peripheral blood stem 
cell transplantation, the patient died 23 months after diagnosis. Lane et al. reported a 
t(9;22)(p24;q11.2) translocation in a 44-year-old male patient with CML, leading to a BCR/JAK2 fusion. 
This time, the breakpoint was located between exon 1 of BCR and exon 17 of JAK2. Two years later, 
Tirado et al. published the case of a 14-year-old male patient with B-acute lymphoblastic leukaemia, 
also featuring a BCR/JAK2 fusion gene.  In 2011, Impera et al. published a case report of a 49-year-old 
woman with an unclassifiable myeloproliferative neoplasm (MPN) with a three-way 
t(9;18;22)(p23;p11.3;q11.2) translocation. Two variants of the BCR/JAK2 fusion gene could be 
detected: A fusion between BCR exon 1 and JAK2 exon 17, and a longer variant fusing BCR exon 1 to 
JAK2 exon 15. The patient, presenting with leukocytosis and hypercellular bone marrow, was 
administered imatinib and dasatinib, which failed to induce a haematological response. The 
treatment was then switched to PEG-interferon therapy, achieving a complete haematological 
response over the course of 10 months. In 2012, a publication by Elnaggar et al. described the case of 
an 84-year-old male patient with CML-like myeloproliferative disease. Similar to the first case 
described by Griesinger et al., sequencing revealed a fusion between exon 1 of BCR and exon 19 of 
JAK2. During the same year, Cuesta-Domínguez et al. published a case description of a 58-year old 
male patient diagnosed with ALL over six years earlier, exhibiting a similar BCR/JAK2 fusion (BCR exon 
1, JAK2 exon 19). After diagnosis, the patient received a “standard high-risk ALL protocol” followed 
by a autologous peripheral blood stem cell transplant and remained in complete remission (at the 
time of the publication in 2012). In 2013, Bellesso et al. reported a 54-year-old male patient with 
CML, featuring the t(9;22)(p24;q11.2) translocation. Again, treatment with imatinib and dasatinib 
proved to be unsuccessful, and the patient died of acute graft-versus-host disease after receiving 
allogeneic bone marrow transplantation. Finally, in 2014, Schwaab et al. published a case report 
featuring the use of the janus kinase-inhibitor Ruxolitinib on two patients with myeloproliferative 
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neoplasms involving JAK2. One of these patients exhibited the BCR/JAK2 (BCR exon 1, JAK2 exon 16) 
fusion and the TKI treatment proved to be initially successful leading to a short-term haematological 
remission (see 4.22). The following table contains a compilation of some key features of these case 
reports. 
Age Gender Phenotype BCR/JAK2 variant Published by: 
63 F CML BCR exon 1, JAK2 exon 19 Griesinger et al., 2005 
67 F AML M1 BCR exon 14, JAK2 exon 11 Cirmena et al., 2008 
44 M CML BCR exon 1, JAK2 exon 17 Lane et al., 2008 
14 M B-ALL No data provided Tirado et al., 2010 
49 F MPN (unclassifiable) BCR exon 1, JAK2 exon 15/17 Impera et al., 2011 
84 M CML-like MD BCR exon 1, JAK2 exon 19 Elnaggar et al., 2012 
58 M ALL BCR exon 1, JAK2 exon 19 Cuesta-Domínguez et al., 2012 
54 M CML No data provided Bellesso et al., 2013 
- - MPN BCR exon1, Jak2 exon 16 Schwaab et al., 2014 
Table 4: A compilation of case reports featuring the BCR/JAK2 fusion gene in patients diagnosed with diseases of the 
bone marrow. 
 
 
1.25 Characterisation of the BCR/JAK2 fusion gene 
In the field of leukaemia research, JAK2 is not an unknown gene. In fact, the ETV6/JAK2 fusion in B- 
and T-ALL, first described in 1997, has been the subject of several publications over the last 15 years. 
The product of the ets variant gene 6 (ETV6), has a helix-loop-helix (HLH) oligomerization domain 
prompting the mutant ETV6/JAK2 fusion protein to oligomerize, leading to autophosphorylation and 
consecutive activation of the JAK2 kinase domain (Peeters et al., 1997). Furthermore, activating 
mutations of JAK2 are a frequent observation in several diseases. The JAK2V617F mutation is a 
nucleotide exchange within exon 14 of the JAK2 gene, resulting in a consecutive overactivation of the 
JAK2 kinase domain. The JAK2V617F is highly prevalent in cases of polycythaemia vera (PV) (up to 
95%), essential thrombocythemia (ET) (up to 50%) and primary myelofibrosis (PMF) (up to 50%), and 
has also been described in rare cases of lymphoblastic leukaemia (James et al., 2005; Baxter et al., 
2005; Tefferi et al., 2007). There are other, more uncommon JAK2 fusion genes linked to a broad 
spectrum of myeloproliferative neoplasms, such as the PCM1-JAK2,  SSBP2-JAK2,  RPN1-JAK2, NF-E2-
JAK2, RUNX1-JAK2 and PAX5-JAK2 fusions (Patnaik et al., 2010). 
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Because of several case reports the BCR/JAK2 fusion gene, a distinct type of tumorigenic JAK2 fusion 
gene, has been brought to attention. Given the broad spectrum of clinical phenotypes and the 
paucity of BCR/JAK2 case reports to date, it is a rewarding subject for clinical and experimental 
research. This fusion gene appears to be relatively rare, however, it might be more common than the 
number of descriptions would suggest. Although a rare finding, it may yield important prognostic and 
therapeutic implications. While some clinicians suggested a negative impact on the patient’s 
prognosis (Tirado et al., 2010), the introduction of TKIs, especially the JAK1/2-inhibitor ruxolitinib, 
may lead to a new therapeutic option for these patients. 
Working with material acquired from the first patient described by Griesinger et al., it is the intention 
of this doctoral thesis to study the transformation potential and functional characteristics of the 
BCR/JAK2 fusion protein.  Assuming a connection between the elevated activity of a mutant JAK2 and 
unrestrained, accelerated cell proliferation, I conducted experiments to characterize and quantify the 
effects of the gene in vitro. 
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2 Materials and Methods 
 
2.1.1 Reagents 
 
Reagent Source 
1-kb-DNA Ladder Invitrogen, Karlsruhe, Germany 
80 -1000 bp Ladder Invitrogen, Karlsruhe, Germany 
Acetic acid Merck, Darmstad, Germany 
Acrylamid Rotiphorese® Gel 30 (37, 5:1) Carl Roth, Karlsruhe, Germany  
Agar select Carl Roth, Karlsruhe, Germany  
Agarose Invitrogen, Karlsruhe, Germany 
Amino acids Sigma-Aldrich, St. Louis, USA 
Ampicillin Ratiopharm, Ulm, Germany 
APS (Ammonium persulfate) Sigma-Aldrich, St. Louis, USA 
Aqua ad iniectabilia Braun B Melsungen AG, Germany 
ß-Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
Big Dye Thermo Fisher Scientific Inc., Waltham, USA 
Bovine serum albumine (BSA) Sigma-Aldrich, St. Louis, USA 
Calcium cloride (CaCl₂) Sigma-Aldrich, St. Louis, USA 
d₂H₂O Millipore, Eschborn, Germany 
DAPI (4',6-diamidino-2-phenylindole) Sigma-Aldrich, St. Louis, USA 
DMSO (dimethyl sulfoxide) Merck, Darmstadt, Germany 
DPBS Thermo Fisher Scientific Inc., Waltham, USA 
dNTP mix Invitrogen, Carlsbad, USA 
EDTA (ethylenediaminetetraacetic acid) Carl Roth, Karlsruhe, Germany 
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Carl Roth, Karlsruhe, Germany 
FBS (Fetal bovine serum) Invitrogen Cell Culture, Karlsruhe, Germany 
Ficoll DNA loading buffer Sigma-Aldrich, St. Louis, USA 
Formamide Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Merck, Darmstadt, Germany 
HEPES (N-(2-Hydroxyethyl) piperazine-N´-(2 
ethanesulfonic acid)) 
Sigma-Aldrich, St. Louis, USA 
Hydrochloridric acid 1M Carl Roth, Karlsruhe, Germany 
Hydrochloridric acid 2M Carl Roth, Karlsruhe, Germany 
Isopropanol Carl Roth, Karlsruhe, Germany 
Klenow Fragment Fermentas, St. Leon-Rot, Germany 
Magnessium Chloride (MgCl₂) Sigma-Aldrich, St. Louis, USA 
Methanol Sigma-Aldrich, St. Louis, USA 
Milk powder Carl Roth, Karlsruhe, Germany 
Page Ruler Prestained Protein Ladder Thermo Fisher Scientific Inc., Waltham, USA 
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Penicillin/streptomycin Thermo Fisher Scientific Inc., Waltham, USA 
Pepsin Sigma-Aldrich, St. Louis, USA 
Peroxidase Sigma-Aldrich, St. Louis, USA 
Polyethylenglycol (PEG) 4000 Merck, Darmstadt, Germany 
Potassium chloride (KCl) Carl Roth, Karlsruhe, Germany 
Protamine sulphate Sigma-Aldrich, St. Louis, USA 
Proteinase K (recombinant), PCR grade Fermentas/ Thermo Fisher Scientific Inc., 
Waltham, USA 
Qiagen Master Mix for PCR Qiagen, Venlo, Netherlands 
Recombinant murine IL3 (rm IL-3) Immunotools GmbH, Germany 
Restriction enzymes Fermentas/ Thermo Fisher Scientific Inc., 
Waltham, USA 
Restriction enzymes NewEngland Biolabs, Schwalbach, Germany 
SDS (sodium dodecyl sulfate) Carl Roth, Karlsruhe, Germany 
Sequencing buffer for PCR Thermo Fisher Scientific Inc., Waltham, USA 
S.O.C. medium Invitrogen, Carlsbad, USA  
Sodium acetate, Anhydrous (NaAC) Merck, Darmstadt, Germany 
Sodium chloride (NaCl) Merck, Darmstadt, Germany 
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany 
Sodium phosphate dibasic anhydrous (Na₂HPO₄) Sigma-Aldrich, St. Louis, USA 
Tris (2-Amino-2-hydroxymethyl-propane-1,3-diol) Carl Roth, Karlsruhe, Germany 
Trypan blue Invitrogen, Karlsruhe, Germany 
Trypsin-EDTA Thermo Fisher Scientific Inc., Waltham, USA 
Tween® 20 Sigma-Aldrich, St. Louis, USA 
X-alpha-gal (5-Bromo-4-Chloro-3-indolyl a-
Dgalactopyranoside) 
Sigma-Aldrich, St. Louis, USA 
Yeast extract Sigma-Aldrich, St. Louis, USA 
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2.1.2 Materials and kits 
 
Material Source 
Blotting paper GB003 and GB002 Schleicher & Schuell, Dassel, Germany 
Coverslips Menzel-Gläser®, Braunschweig, Germany 
Cryotube™ Vials Nalge Nunc International, Denmark 
Endofree® Plasmid Maxi kit Qiagen, Hilden, Germany 
Eppendorf tubes Eppendorf, Hamburg, Germany 
FACS Polystrene round-bottom tubes Becton Dickinson, Meylan, France 
Falcon™ Round-Bottom Polypropylene Tubes Thermo Fisher Scientific Inc., Waltham, USA 
Falcon™ 50ml conical tubes Thermo Fisher Scientific Inc., Waltham, USA 
Ficoll type 400 Sigma-Aldrich, St. Louis, USA 
Filter unit 0.22 µm Millipore, Belford, USA 
Filter unit 0.45 µm Millipore, Belford, USA 
Glass beads Sigma-Aldrich, St. Louis, USA 
Glassware Schott, Jena, Germany 
Hemocytometer/ Neubauer counting chamber Merck, Darmstadt, Germany 
Microcentrifuge tube (1.5 ml) Eppendorf, Hamburg, Germany 
Microscope slides Menzel-Gläser®, Braunschweig, Germany 
Parafilm SPI supplies, West Chester, USA 
PCR Mycoplasma Test Kit AppliChem Inc., St- Louis, USA 
Pipettes (manual) Eppendorf, Hamburg, Germany 
Pipette tips Eppendorf, Hamburg, Germany 
Pipette tips Starlab Group, Hamburg, Germany 
Plasmid Quiaquick Miniprep-kit Qiagen, Hilden, Germany 
Plastic cuvettes for biophotometer Carl Roth, Karlsruhe, Germany 
Plastic ware for cell culture Sarstedt, Nümbrecht, Germany 
Plastic ware for cell culture Corning Inc., New York, USA 
Plastic ware for cell culture Sigma-Aldrich, St. Louis, USA 
PVDF-Membrane Hybond-P Amersham Thermo Fisher Scientific Inc., Waltham, USA 
QIAquick gel extraction kit Qiagen, Hilden, Germany 
Qproteome Mammalian Protein Prep Kit Qiagen, Hilden, Germany 
S.O.C. medium Invitrogen, Carlsbad, USA 
Super Signal West Pico Chemiluminescent 
Substrate Kit 
Thermo Fisher Scientific Inc., Waltham, USA 
Surgical blades B. Braun Melsungen, Melsungen, Germany 
Syringes B. Braun Melsungen, Melsungen, Germany 
Tween® 20 Sigma-Aldrich, St. Louis, USA 
Whatman paper Sigma-Aldrich, St. Louis, USA 
Wipes Kimberly Clark, Dallas, USA 
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2.1.3 Restriction enzymes and buffers 
 
Enzyme or Buffer Composition Source 
BamH1  BamH1, 10U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xBuffer BamH1 Tris-HCl (pH8.0) 
MgCl₂ 
KCl 
TritonX-100 
BSA 
100mM 
50mM 
1M 
0.2% 
1mg/ml 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
EcoR1 EcoR1, 10U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xBuffer EcoR1 Tris-HCl (pH7.5) 
MgCl₂ 
NaCl 
TritonX-100 
BSA 
500mM 
100mM 
1M 
0.2% 
1mg/ml 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
Esp31 (BsmB1) Esp31, 10U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xBuffer Tango Tris-acetate (pH7.9) 
Mangnesium acetate 
Potassium acetate 
BSA 
DTT 
330mM 
100mM 
660mM 
1mg/ml 
10mM 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
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Enzyme or Buffer Composition Source 
FastAP Thermosensitive 
Alkaline Phosphatase 
Alkaline phosphatase, 1U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xFastAP Buffer Tris-HCl (pH8.0) 
MgCl₂ 
KCl 
TritonX-100 
BSA 
100mM 
50mM 
1M 
0.2% 
1mg/ml 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
Fse1 Fse1, 2U/µl New England Biolabs GmbH, 
Ipswich, USA 
10xNEBuffer 4 Potassium acetate 
Tris-acetate 
Magnesium acetate 
DTT 
500mM 
200mM 
100mM 
10mM 
New England Biolabs GmbH, 
Ipswich, USA 
Klenow Fragment Klenow Fragment, 10U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xReaction Buffer Tris-HCl (pH 8.0) 
MgCl₂ 
DTT 
500mM 
50mM 
10mM 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
Not1 Not1, 10U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
10xBuffer 0 Tris-HCl (pH 7.5) 
MgCl₂ 
NaCl 
BSA 
500mM 
100mM 
1M 
1mg/ml 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
Sac2 Sac2, 20U/µl New England Biolabs GmbH, 
Ipswich, USA 
T4 DNA Ligase T4 DNA Ligase, 5U/µl Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
 25 
10xT4 DNA Ligase Buffer Tris-HCl 
MgCl₂ 
DTT 
ATP 
400mM 
100mM 
100mM 
5mM 
Fermentas/ Thermo Fisher 
Scientific Inc., Waltham, USA 
 
 
 
 
2.1.4 Buffers and Solutions 
 
2.1.4.1  Buffers and Solutions used for plasmid preparation 
 
Buffer Composition Source 
10x TE buffer Tris-HCl pH 7.5 
EDTA 
100 mM 
10 mM 
Qiagen, Hilden, 
Germany 
Alkaline lysis buffer for plasmid 
preparations 
(Buffer P2, Qiagen) 
NaOH 
SDS 
200 mM 
1% 
Qiagen, Hilden, 
Germany 
Neutralization buffer for plasmid 
preparations 
(Buffer P3, Qiagen) 
Potassium acetate 
pH 5.5 
3 M Qiagen, Hilden, 
Germany 
Resuspension  buffer for plasmid 
preparations 
(Buffer P1, Quiagen) 
Tris-HCl, pH 8.0 
EDTA 
RNase A 
50 mM 
10 mM 
100 μg/ml 
Qiagen, Hilden, 
Germany 
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2.1.4.2 Buffers and solutions used in cell culture 
 
Solution Composition  Source 
2x HBS Type A HEPES 
KCl 
NaCl 
Na₂HPO₄ 
pH 7.05 
50 mM 
12 mM 
280 mM 
1.5 mM 
2x HBS Type B HEPES 
NaCl 
NaP 
pH 7.2 
50 mM 
280 mM 
1.5 mM 
Bufer SE EDTA 
Tris-HCl pH 8.0 
NaCl 
10 mM 
100 mM 
1 M 
Qiagen, Hilden, 
Germany 
 
 
 
 
2.1.4.3 Buffers and solutions used for western blotting 
 
Solution Composition 
10x Electrophoresis buffer Tris-HCl 
Glycine 
SDS 
250 mM 
1.92 M 
1 % 
Transfer Buffer Tris-HCl 
Glycine 
SDS 
Methanol 
20 mM 
15.4 mM 
0.8 % 
20 % 
1x TBS Tris-HCl pH 8.0 
NaCl 
10 mM 
150 mM 
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Separating gel (8,55%) 
 
HPLC grade H₂O 
Bisacrylamide 38% 
1.5 M Tris-HCl pH 8.8 
SDS 10%  
APS 10% 
Temed 
5.55 ml 
2.25 ml 
1.875 ml 
100 μl 
110 μl 
12 μl 
Stacking gel HPLC grade H₂O 
Bisacrylamide 38% 
1 M Tris-HCl pH 6.8 
SDS 10% 
APS 10% 
Temed 
3.685 ml 
630 μl 
625 μl 
50 μl 
65 μl 
12 μl 
1x TBS-T Tris-HCl pH 8.0 
NaCl 
Tween® 20 
10 mM 
150 mM 
0.1 % 
 
 
2.1.4.4 Antibodies for western blotting 
 
Antibody Source 
JAK2 (D2E12)XP® Rabbit mAb Cell Signaling Technology, 
Cambridge, UK 
α Rabbit igG Peroxidase Sigma-Aldrich, St. Louis, USA 
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2.1.5 Bacteria culture medium 
 
Medium Composition 
LB medium (liquid) Tryptone  
Yeast extract 
NaCl 
1 % 
0.5 % 
1 % 
LB medium for agar plates Tryptone  
Yeast extract 
NaCl 
Agar select 
Ampicillin 
1 % 
0.5 % 
1 % 
1.5 % 
50 μg/ml 
 
The ingredients for culture medium or agar plates where dissolved in dH₂O and then autoclaved. In 
order to select transformants, 50μg/ml ampicillin was added to the LB medium for agar plates. It was 
then poured into Petri dishes, dried overnight and stored at +4°C. Similarly, 50μg/ml ampicillin was 
added to LB medium used for liquid cultures of transformed bacteria. 
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2.1.6 Eukaryote culture medium 
 
Medium Composition Source 
Gibco® DMEM (Dulbecco’s Modified 
Eagle medium) cell culture medium 
 
 
 
 
Thermo Fisher 
Scientific Inc., 
Waltham, USA 
DPBS (Dulbecco's Phosphate-Buffered 
Saline) 
Thermo Fisher 
Scientific Inc., 
Waltham, USA 
Gibco® RPMI (Roswell Park Memorial 
Institute culture medium) cell culture 
medium 
Thermo Fisher 
Scientific Inc., 
Waltham, USA 
Culture Medium for BaF3 cells 
 
 
Gibco® RPMI 
FBS  
WEHI-medium 
Penicillin/streptomycin 
80 % 
10 % 
10 % 
100 μg/ml 
 
Culture medium for Phoenix Ecotrophic 
cells 
 
Gibco® DMEM 
FBS 
Penicillin/streptomycin 
85 % 
15 % 
100 μg/ml 
Culture medium for WEHI cells 
 
 
Gibco® RPMI 
FBS 
Penicillin/streptomycin 
90 % 
10 % 
100 μg/ml 
 
 
 
 
 
 
 
 
 
 
 30 
2.1.7 Bacterial strains 
 
Strain Usage Genotype Source 
DH5α™ 
competent cells 
Plasmid 
amplification 
 
Invitrogen, 
Carlsbad, 
USA 
XL10-gold 
ultracompetent 
cells 
Plasmid 
amplification 
 
Agilent 
Technologies, 
Santa Clara, 
USA 
 
 
2.1.8 Mammalian cell lines 
 
Cell line Detail 
Ba/F3 Mouse pro B-cells, IL-3 dependent line derived from the C3H mouse strain. 
Phoenix ecotrophic Packaging cell line producing gag-pol and envelop proteins for 
ecotropic viruses such as pMIG; derivative of 293T cell line. 
WEHI A myelomonocytic leukemia cell line established from inbred BALB/c mice, 
capable of producing IL-3. 
 
 
2.1.9 Human sample 
 
Human cDNA derived from the blood sample of a 63-year-old female patient with chronic 
myelogenous leukemia at the Klinikum Grosshadern medical facility, was used to amplify the 
BCR/JAK2 breakpoint fragment via PCR. The amplification product was cloned into the pCR2.1 TOPO® 
vector to serve as a starting point for further cloning steps. 
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2.1.10 Plasmids 
 
Plasmid  Usage Resistance Source 
pcDNA3 Cloning vector Ampicillin Invitrogen, 
Carlsbad, USA 
pCR2.1 TOPO ® Cloning vector with 3'-thymidine (T) overhangs for 
direct ligation of PCR products. 
Ampicillin Invitrogen, 
Carlsbad, USA 
pMIG Retroviral vector containing GFP, used for gene 
expression in mammalian cells. 
Ampicillin Addgene, 
Cambridge, 
USA 
 
 
2.1.11 Constructs 
 
Construct Usage Source 
pcDNA3 BCR/ABL Expression construct for BCR/ABL, used during the 
cloning process of the BCR/JAK2 fusion gene. 
Prof. Dr. Stefan K 
Bohlander 
pcDNA3 ETV6/JAK2 Expression construct for ETV6/JAK2, used during the 
cloning process of the BCR/JAK2 fusion gene. 
Prof. Dr. Stefan K 
Bohlander 
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2.1.12 Oligonucleotides 
 
Primer Sequence Purpose 
5’ BCR sense primer 5’-CAGAACTCGCAACAGTCC-3’ Amplification of the BCR/JAK2 
breakpoint fragment and 
verification of the cloning process 
3’ JAK2 antisense primer 5’-TCATACCGGCACATCTCCACAC-3’ Amplification of the BCR/JAK2 
breakpoint fragment and 
verification of the cloning process 
BCR reverse primer 3’-GCTCGAAGTTGGACCTGAG-5’ Verification of the cloning process 
pcDNA3 reverse primer 3’-GCGATGCAATTTCCTCATTT-5’ Verification of the cloning process 
pMIG reverse primer 3’-GAGGAACTGCTTCCTTCACG-5’ Verification of the cloning process 
pMIG reverse primer 2 3’- TGCCGGTCATAGCTCTTCTT-5’  Verification of the cloning process 
 
 
2.1.13 Equipment 
 
Equipment Source 
Analytical balance Mettler AE 240 Mettler-Toledo, Greifensee, Switzerland 
Analytical balance Mettler PM 2000 Mettler-Toledo, Greifensee, Switzerland 
Centrifuge Eppendorf 5417C Eppendorf, Hamburg, Germany 
Centrifuge Heraeus Megafuge 16R Heraeus, Hanau, Germany 
Centrifuge Labofuge 400 Thermo Fisher Scientific Inc., Waltham, USA 
Centrifuge Sorvall® GLC-2B General Laboratory 
Centrifuge 
DuPont Instruments, Wilmington, USA 
Electrophoresis power supply Gibco® BRL Life Technologies, Carlsbad, USA 
Flow cytometer DakoCytomation MoFlo-
Cellsorter 
Blue Lion Biotech, Carnation, USA 
Freezer (+4°C) Liebherr-International AG, Bulle, Swizerland 
Freezer (-20°C) Liebherr-International AG, Bulle, Swizerland 
Freezer (-80°C) Hera Freeze Heraeus, Hanau, Germany 
Illumination unit Vilber Luroma Vilber Lourmat Deutschland GmbH, Eberhardzell 
Germany 
Incubator (Used for cell culture) Heraeus, Hanau, Germany 
Incubator  Cytoperm (Used for cell culture) Heraeus, Hanau, Germany 
Incubator (Used for bacterial culture) Heraeus, Hanau, Germany 
Incubator (Including a shaker, used for bacterial 
culture) 
New Brunswick Scientific Inc., New Jersey, USA 
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Laboratory bench SCALA Secuflow Waldner Laboreinrichtungen GmbH & Co. KG, 
Wangen, Germany 
Laboratory bench Safe 2020 Thermo Fisher Scientific Inc., Waltham, USA 
Laboratory bench Heraeus LaminAir® HA 2248GS Heraeus, Hanau, Germany 
Laboratory water bath GFL® 1083 GFL - Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany 
Laboratory water bath GFL® 1086 GFL - Gesellschaft für Labortechnik mbH, 
Burgwedel, Germany 
Magnetic stirrer Ikamag REO Heidolph, Schwabach, Germany 
Microscope Axioplan Carl Zeiss, Jena, Germany 
Microscope Diavert Leitz, Wetzlar, Germany 
Microwave Robert Bosch GmbH, Gerlingen, Germany 
PCR machine GeneAmp PCR System 9600 PerkinElmer Inc., Waltham, USA 
pH meter Mettler-Toledo, Greifensee, Switzerland 
Pipette (automatic) Accu-Jet® Pro Brand GMBH + CO KG, Wertheim, Germany 
Plate shaker Heidolph, Schwabach, Germany 
Printer Mitsubishi P93 Mitsubishi, Japan 
Sequencer ABI PRISM™ 310 Genetic Analyzer Applied Biosystems, Foster City, USA 
Spectrophotometer Gene Quant II RNA/DNA 
Calculator 
Pharmacia Biotech, Uppsala, Sweden 
Thermal cycler Biometra Trio Thermoblock Biometra GMBH, Goettingen, Germany 
Transilluminator 302nm Ultra-Violet Products Ltd, Cambridge, UK 
Vortex Mixer Janke & Kunkel (IKA), Staufen im Breisgau, 
Germany 
Vortex Mixer Heidolph REAX 2000 Heidolph, Schwabach, Germany 
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2.2 Methods 
 
2.2.1 Microbiology techniques 
 
2.2.1.1 Bacterial cultures for plasmid amplification 
In order to amplify plasmids, E. coli strain DH5α were transformed with the plasmids to be amplified. 
Cultures of Ecoli DH5α™ competent cells stored at -80°C were thawed on wet ice and gently stirred. 
A 50μl aliquot of the culture was transferred to an 1.5ml epi tube, 10ng of plasmid DNA were added 
to the tube and the contents were gently mixed. After incubation on wet ice for 30 minutes, a heat 
shock was applied by dipping the tube into a 37°C water bath for 20 seconds. Afterwards, the tube 
was cooled on wet ice for another 2 minutes before adding 950μl of liquid LB medium pre-warmed to 
37°C. The tubes were then kept in a 37°C shaking incubator at 150 rpm for 1 hour. A total of 4 plates 
of LB agar containing 50μg/ml ampicillin were used to select transformant colonies. 100μl, as well as 
250μl of the culture were streaked out on 2 plates each, in order to increase the probability of single, 
distinguishable cultures on the following day. A negative control of Ecoli DH5α™, which was 
previously treated like the transformed culture with the exception of not receiving any plasmid DNA, 
was streaked out on two additional agar plates (100μl and 250μl) to confirm the effectiveness of the 
antibiotic-based selection process. A total of 6 plates were incubated at 37°C overnight or for at least 
16 hours. The next day, single colonies were picked and transferred to 14ml Falcon™ tubes 
containing 5ml of liquid LB medium with 50μg/ml ampicillin. Again, the tubes were kept in a 37°C 
incubator at 150rpm for 16 hours. The next day, the liquid cultures were harvested for plasmid 
preparation. 
When working with bacteria transformed with the pCR2.1 TOPO ® plasmid, 80μl of a 2% x-alpha-gal 
solution were streaked out on each agar plate prior to the addition of bacteria. The plasmid itself 
contains the lacZ gene coding for the enzyme β-galactosidase, which spans the polylinker region. Any 
insert within this region will lead to the disconnection of lacZ and therefore a lack of β-galactosidase 
acitvity. The enzyme cleaves the colorless X-gal into galactose and a product which turns blue after 
dimerisation and oxidation. This process was utilized to distinguish colonies containing empty 
plasmids, which would still be capable of the production of β-galactosidase and will therefore be blue, 
and colourless colonies containing plasmids with an insert. 
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2.2.1.2 Bacterial cultures for the amplification of clones from a ligation reaction 
When working with the product of a ligation reaction, a more efficient bacterial cell line was 
sometimes required to obtain a reasonable number of transformant colonies. In these cases, the 
XL10-gold ultracompetent cells were put to use. After thawing on wet ice, an aliquot of 25μl was 
transferred to an 1.5ml epi tube, 1μl of ß-mercaptoethanol was added and the mixture was gently 
stirred. The tube was then kept on wet ice for 10 minutes. Afterwards, 5μl of the ligation reaction 
mixture were added, the contents of the tube were gently stirred and the mixture was incubated on 
ice for another 30 minutes before a heat shock was applied by dipping the tube into a 42°C water 
bath for 30 seconds. The tube was cooled down on ice for 2 minutes and 975μl of pre-warmed SOC 
medium were subsequently added. After incubating the epi tubes at 37°C and 150rpm for 40 minutes, 
the content was streaked out on LB agar plates containing 50μg/ml ampicillin as described in 2.11. 
 
2.2.1.3 Preparation of glycerol stocks 
In order to prepare the long-term archiving of plasmid-bearing bacteria, 800μl of a 16-hour liquid 
culture (As described in 2.11) were mixed with 200μl of glycerol. The mixture was then frozen and 
stored in a -80°C freezer. 
 
2.2.2 Molecular biology techniques 
 
2.2.2.1 Preparation of plasmids from bacterial cultures 
5ml liquid cultures were harvested by centrifugation at 3000rpm for 10 minutes. The plasmid DNA 
was isolated with Quiagen’s Quiaquick Miniprep-kit, utilizing the buffers and solutions included in the 
kit and closely following the instructions provided by the manual. During the final step, the DNA 
obtained from a 5ml liquid culture was usually diluted in 50μl TE buffer and stored at -20°C for 
further use. 
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2.2.2.2 Isolation of the pMIG plasmid prior to the transfection of mammalian cell lines 
Since the transfection of mammalian cell lines required highly purified, endotoxin-free DNA, 
Quiagen’s Endofree® Plasmid Maxi kit was used to obtain plasmid DNA from 20ml liquid overnight 
cultures. The purified plasmids where diluted in HPLC grade H₂O and stored at -20°C. 
 
2.2.2.3 Isolation of genomic DNA from mammalian cell lines 
To isolate genomic DNA, the contents of a 15ml culture were centrifuged, the supernatant was 
discarded and the pellet was frozen at -20°C for 10 minutes. After thawing, the cells were 
resuspended with PBS and transferred to a 1.5ml Eppendorf tube. After 2 additional washing steps of 
centrifugation and resuspension with PBS, the pellet was resuspended with 150μl SE (Saline-EDTA) 
Buffer, 30μl 10% SDS and 2.5μl 10mg/ml Pronase. The mixture was then incubated in a 55°C water 
bath for 3 hours, before 150μl of SE buffer were added and the mixture was incubated for another 10 
minutes at 55°C. Then, 100 μl of 5M NaCl solution were added and the solution was vortexed gently 
and centrifuged. The supernatant, now containing the DNA, was transferred to another Eppendorf 
tube and precipitated by the addition of 750μl of ice-cold 98% ethanol. After centrifugation, another 
washing step containing 70% ethanol was applied and the pellet was then air-dried for several 
minutes. Finally, the DNA was resuspended in TE buffer on a plate shaker at 4°C overnight and stored 
at -20°C for further use. 
 
2.2.2.4 Agarose gel electrophoresis 
During the cloning process, new plasmid samples acquired from bacterial cultures were usually 
subjected to a series of experiments to verify the presence of an insert or to determine the 
orientation of the insert. The plasmid DNA was cleaved by different restriction enzymes and the 
fragments were visualized by agarose gel electrophoresis. Depending on the size of these fragments, 
different concentrations of agarose were used. Agarose concentrations of 0.8%, 1% or 2% allowed to 
visualize and distinguish fragments ranging from 50 bp to several kb. Depending on the requirements 
of the experiment, 0.8g, 1g or 2g of agarose were diluted in 100ml TE buffer and heated until 
reaching the boiling point at least twice. The solution was cooled down in a 55°C water bath for 
several minutes, before 5μl of 10g/l ethidium bromide solution were added, aiming at a final 
concentration of 0.5μg/ml ethidium bromide. The gel was poured into the gel tray and left to solidify 
at room temperature for at least 1.5 hours. The gel was then put into the electrophoresis chamber, 
filled with TAE buffer. The DNA samples were prepared with Ficoll DNA loading buffer and carefully 
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pipetted into the gel pockets. A DNA size marker was added in the form of a 1-kb, or 80-1000 bp DNA 
ladder and the fragments were separated by the application of an electrical current. Usually, an 
electric potential of 80V was applied for 10 minutes and subsequently increased to 110V for the 
following 30 to 90 minutes. After separation, DNA fragments were visualized using a 302nm 
transilluminator. 
 
2.2.2.5 Isolation of DNA fragments for cloning 
Given its mutagenous effects, DNA fragments intended for cloning purposes were required to be 
isolated without the application of ethidium bromide. To achieve this, an agarose gel was prepared 
according to 2.224 but without the addition ethidium bromide. The digested DNA was pipetted into 3 
gel pockets: The largest quantity, usually the bulk of the reaction, was placed in the middle, while 
smaller quantities were placed to the left and right to indicate the position of the desired DNA 
fragment later on. A normal gel electrophoresis was performed and the gel was then sliced into 3 
parts: Two parts, each containing one of the outer gel pockets and the narrow part in the middle. The 
two outer parts were stained in TAE buffer containing 2μg/ml EtBr for 5 minutes. The gel was 
subsequently put back together on the transilluminator, and the visible EtBr-stained bands could be 
used as indicators for cutting out the desired DNA band of the EtBr-free middle part. The DNA was 
then isolated using the QIAquick gel extraction kit, the weight of the cut-out gel fragment was 
determined and the quantities of buffers and solutions were adjusted accordingly. The DNA was 
resuspended in TE buffer and stored at -20°C. 
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2.2.2.6 Cloning reactions 
Cloning reactions were planned with regard to several features of the DNA fragments involved. 
Depending on the size of the fragments, different quantities of plasmid and insert were required to 
gain a maximum number of correctly ligated plasmids. Again, these numbers changed depending on 
the nature of the fragment’s endings (i.e. blunt or sticky ends). Sambrooks and Russel’s Molecular 
Cloning: A Laboratory Manual (Green MR, Sambrook S, 2001) was of great help, providing the tables 
needed to determine the optimal ratio of plasmid and insert and information regarding the cloning 
process in general. 
Prior to the cloning reaction, the ends of the plasmid fragment were usually dephosphorylated using 
alkaline phosphatase to prevent intramolecular ligation and to minimize the number of empty 
plasmids. T4 DNA ligase was used for the ligation reaction, which was kept on ice overnight. The 
ligase was inactivated the next day and the sample was stored at -20°C. 
 
2.2.2.7 Enzymatic digestion 
During the cloning process, a variety of experiments involving different restriction enzymes were 
conducted. The enzymes and the corresponding buffers, as listed under 2.1.3, were applied 
according to the manual provided by the producer. After incubation, the enzymes were inactivated 
and the samples were stored at -20°C for further use. 
 
2.2.2.8 Elimination of cutting sites 
In order to remove a BamH1 cutting site of the pCR2.1 plasmid, the plasmid was digested by BamH1, 
the enzyme was inactivated and a new reaction with Klenow fragment and dTNPs was carried out to 
fill up the overhangs. With the ends blunted,, the plasmid was religated using T4 DNA ligase, thus 
eliminating the BamH1 site. Accordingly, after amplification by bacterial culture, the plasmid could 
no longer be linearized by BamH1. 
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2.2.2.9 Polymerase chain reaction (PCR) 
Polymerase chain reaction was used to amplify the BCR/JAK2 breakpoint fragment from the cDNA 
patient sample prior to cloning it into the pCR2.1 plasmid. A master mix containing Taq polymerase 
and dTNPs supplied by Quiagen was used for the reaction. The 5’ BCR sense primer and the 3’ JAK2 
antisense primer (see 2.1.12) were applied and the PCR machine was programmed with the protocol 
shown in table 5. 
Steps Temperature (°C) Time (min) Frequency 
Initial denaturation 95 5 Once 
Denaturation 95 1  
40 cycles Annealing 58 1 
Elongation 72 1 
Final elongation 72 3 Once 
Cooldown 4 ∞ Once 
Table 5: PCR protocol used for the amplification of the BCR/JAK2 breakpoint fragment. 
The amplification product of 358 bp was then visualized by agarose gel electrophoresis as shown in 
figure 8. 
 
2.2.2.10 Sequencing  
During the cloning process, it was necessary to assure the integrity and completeness of the fusion 
gene, especially since mutations are known to occur during plasmid amplification in bacterial hosts. 
While sequencing of larger DNA segments was usually performed by the SEQLAB Sequence 
Laboratories GmbH in Göttingen, the breakpoint fragment was sequenced in our laboratory after 
cloning into the pCR2.1 plasmid. The modified Sanger sequencing method was applied, utilizing 
fluorescent dyes and a sequencing machine capable of capillary electrophoresis. Two sequencing 
reactions, containing the plasmid DNA, sequencing buffer, big dye and either the 5’ BCR sense primer 
or the 3’ JAK2 antisense primer were prepared and the thermal cycler was programmed with the 
protocol shown in table 6.  
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Steps Temperature (°C) Time (s) Frequency 
Initial denaturation 95 180 Once 
Denaturation 95 20  
28 cycles Primer annealing 58 20 
Elongation 60 180 
Final elongation 60 120 Once 
Cooldown 4 ∞ Once 
Table 6: Thermal cycling protocol used for linear amplification of single strands prior to sequencing. 
In order to cover the region of interest, a relatively small number of primer oligonucleotides were 
required, given the long range and high quality of the sequencing performed by the SEQLAB 
Sequence Laboratories Göttingen GmbH. 
 
2.2.3 Cell culture techniques 
 
2.2.3.1 Cultivation of mammalian cells 
All cell lines, which were utilized during the cell culture stage, were kept in an incubator at 37°C and 
only removed for maintenance or to conduct experiments. The components of the culture medium 
of each cell line can be found in 2.1.6. In both RPMI and DMEM medium, a depletion of nutrients was 
indicated by a colour change from red to yellow. When the colour change occurred, four fifths of the 
flask’s volume were usually discarded or used to acquire cells for storage (see 2.2.3.3), new medium 
was added to the rest and the flask was returned to the incubator. The cells were frequently counted 
using a Neubauer counting chamber. Depending on the estimated density of cells, the medium was 
diluted with trypan blue at two different ratios (For example 1:5 and 1:10), and 10μl of each dilution 
were transferred to one of the two slots of the Neubauer plate. In order to determine the number of 
cells per ml, the average value of both counts was used in the calculation.  
Cultivation of the adherent Phoenix Ecotrophic packaging cell line required harvesting of the cells for 
storage, counting, and medium changes. The cell cultureconsisted ofa thin, continuous layer of cells 
adhereing to the bottom of the flask. The original medium was discarded and the cells were washed 
with pre-warmed (37°C) PBS. After the PBS was discarded, a trypsin-EDTA solution was added and 
the flask was returned to the 37°C incubator for 4 minutes. After the cells had detached from the 
 41 
surface, they were suspended in pre-warmed culture medium and residual cell clusters were 
dissolved by pipetting the medium up and down repeatedly. The cell solution could now be split 
between flasks in order to expand the culture. 
Maintenance of the semi-adherent WEHI cell line, which was cultivated for the production of IL-3 
conditioned medium, required similar measures. While the majority of cells were growing in 
suspension, a number of cells were attached to the flask’s surface. After incubation with DPBS 
(without Ca2+ or Mg2+) for 10 minutes at 37°C, these were usually detached using a scraper and 
residual chunks were dissolved mechanically by pipetting. 
The IL-3 dependent BaF3 cell line, which was the main object of study, proved to be robust and 
rather simple to maintain. Since the cells grew unattached to a surface, they were mixed simply by 
pipetting the medium up and down prior to counting, freezing, medium change or expansion of the 
cultures. 
 
2.2.3.2 Production of IL-3 conditioned culture medium 
The WEHI cell line, capable of the production of IL-3, was cultivated for the single purpose of 
harvesting IL-3 conditioned medium required to maintain the BaF3 cell line. WEHI cultures were 
harvested by centrifugation and the supernatant was filtered through a 0.22μm filter and stored at -
20°C. 
 
2.2.3.3 Freezing and thawing of cells 
In order to create long-time stocks of a certain cell line, the contents of a culture flask were mixed 
thoroughly and the number of cells per ml was determined as described in 2.2.3.1. Based on the cell 
number, a volume containing approximately 10⁷ cells was transferred to a 50ml Falcon tube and 
centrifuged. The supernatant was discarded and the pellet was resuspended with 1ml of freezing 
medium consisting of 90% FBS and 10% DMSO (dimethyl sulfoxide). The solution was pipetted into a 
1.5ml Cryotube™, which was placed in a freezing container. The container was put into a -80°C 
freezer overnight and the next day, the Cryotube™ was transferred to a regular storage box and kept 
at -80°C. This method was often modified: Medium containing a multiple of 10⁷ cells was centrifuged, 
a greater volume of freezing medium was added and the solution was split up between several 
freezing tubes, each containing roughly 1x10⁷ cells. 
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Since slow thawing could potentially damage the cells, the process was accelerated by dipping the 
tubes, recovered from storage at -80°C, in a 37°C water bath. After thawing, the cells were 
transferred to a 50ml falcon tube, filled with 25ml of the corresponding culture medium and the 
contents were mixed and centrifuged. The supernatant was discarded and the pellet was 
resuspended in culture medium, now ready to be transferred to appropriate culture flasks. The 
washing step served to reduce the exposure to DMSO, which would be harmful to the cells at room 
temperature. 
 
2.2.3.4 Transfection of adherent cells 
The Phoenix Ecotrophic cells, derived from the 293T human embryonic kidney cell line, were used as 
a packaging cell line for the retroviral pMIG plasmid. In short terms, Phoenix-ECO cells express the 
Pol gene, coding for reverse transcriptase, the Gag gene, coding for retroviral group antigens, and 
genes coding for viral packaging proteins. The cells are therefore capable of producing fully-
functional retroviral particles as soon as they are transfected with a retroviral vector.  
For transfection with the pMIG vector, the CaPO₄ precipitation method was chosen. The day before 
the transfection, 10cm cell culture plates were filled with 10ml DMEM medium supplemented with 
10% FBS and 1% penicillin/streptomycin mixture and 6.5x10⁶ cells were seeded on each plate. These 
were incubated at 37°C overnight, and the next day, approximately 4 hours before the transfection, 
they were given a whole medium change. The transfection was performed as follows: A 500μl 
mixture was prepared in a 1.5ml tube consisting of 10-15μg Plasmid DNA, 50μl of a 2M CaCl₂ and a 
variable volume of HPLC grade water. The mixture was added dropwise to another tube containing 
500μl of 2x HBS Type A (See 2.1.4.2), the contents were mixed by gently shaking the tube and 
incubated at room temperature for 4 minutes. Drop by drop, the mixture was then evenly distributed 
on each of the culture plates, which were by now covered by a monolayer of Phoenix-ECO cells. After 
swirling, the plates were put back into the incubator and kept at 37°C overnight. On the following 
morning, the culture medium was changed to remove calcium crystals which could be toxic to the 
cells. Starting 12 hours after the medium change, virally-conditioned medium (VCM) was ready to be 
harvested. 
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2.2.3.5 Production of virally-conditioned medium 
12 hours after the last medium change, the supernatant of the transfected Phoenix-ECO cultures was 
harvested with a 10ml syringe and passed through a 0.45μm filter unit into a Falcon tube. 10ml of 
pre-warmed, fresh medium was added to the cells and the plates were returned to the incubator, 
while the collected VCM was stored at -20°C. The procedure was repeated twice, each time after a 
minimum interval of 12 hours. After the third VCM collection, the culture plates were discarded. 
 
2.2.3.6 Transduction of BaF3 cells 
To examine the trasnforming potential of the BCR/JAK2 fusion, two stable cell lines had to be 
established: A BaF3 cell line transduced with pMIG carrying the BCR/JAK2 fusion gene, and a BaF3 
line carrying the empty pMIG vector, serving as a negative control for further experiments.  
Prior to the transduction, BaF3 cell cultures were counted and harvested. An aliquot of WEHI-
conditioned culture medium, virally-conditioned medium, protamine sulphate and BaF3 cells was 
gently mixed in a falcon tube and distributed between 4 wells of a 6-well plate. In total, 1.5ml of 
culture medium, 1.5ml of VCM, 0.6μl of a 5g/l protamine sulphate solution and 0.75x10⁶ cells were 
added to each well. In the absence of an appropriate centrifuge with temperature-control, the 6-well 
plate was centrifuged at 1200rpm for 90 minutes at room temperature, possibly reducing the 
efficiency of the transduction protocol (Originally, the protocol required centrifugation with 2500rpm 
for 90 minutes at 30°C). Afterwards, the cells were put back into the 37°C incubator for 2.5 hours and 
2ml of fresh medium were subsequently added to each well. The next day, the cell cultures were 
transferred to culture flasks and expanded, until a sufficient quantity of cells was available for sorting.  
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2.2.3.7 Testing for mycoplasma contamination 
Before the cells could be sorted, the cultures had to be tested for mycoplasma infection in order to 
prevent contamination of the flow cytometer. To ensure a high sensitivity, a PCR kit (AppliCem’s PCR 
Mycoplasma Test Kit) was put to use. Cell culture supernatant from the transduced BaF3 cell lines 
was prepared according to the protocol and with these samples, as well as a positive control sample, 
a PCR amplification was carried out. The amplification products were analyzed by conventional 
agarose gel electrophoresis, which did not reveal any kind of mycoplasma-specific amplification 
product in the cell culture samples. Therefore, mycoplasma contamination was ruled out and the 
transduced cell lines could be purified by sorting.  
 
2.2.3.8 Establishing a stable transduced cell line 
To acquire a stable cell line for further experiments, successfully transduced cells had to be sorted 
out and purified. The sorting process was based on the expression of GFP, located on the retroviral 
pMIG vector. GFP (green fluorescent protein) exhibits green fluorescence when exposed to blue or 
ultraviolet light, indicating the successful integration of the vector into the genome of the cell. While 
the outcome of the retroviral transduction described in 2.2.3.6 could not be determined right away, 
the flow cytometry was providing valuable data regarding the efficiency of the process.  
In preparation of the sorting process, the cells were harvested by centrifugation and 10⁷-10⁸ cells of 
each culture were resuspended in 1ml of PBS. Additionally, the cells were stained with DAPI, allowing 
the exclusion of dead cells. The samples were then sorted in the Flow Cytometry Core Facility of the 
Phillipps University Marburg’s clinic for hematology and oncology based on the expression of GFP 
and DAPI uptake, using the DakoCytomation MoFlo-Cellsorter. In total, three rounds of sorting were 
necessary to acquire sufficient numbers of GFP positive cells. It is worth notice, that the first round of 
sorting revealed a rather small ratio of GFP expression in the transduced cultures: Only 0.14% of the 
BaF3 cells transduced with pMIG-BCR/JAK2 were GFP positive, along with a GFP expression of 0.75% 
in the culture transduced with the empty pMIG vector. The second round yielded significantly higher 
numbers, with a GFP expression ratio of 93.1% within the pMIG-BCR/JAK2, and 82.77% within the 
empty vector cell line, demonstrating the efficiency of the process.  
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2.2.3.9 Proliferation assays 
T o examine the transforming potential of the BCR/JAK2 gene, proliferation assays containing virally 
transduced BaF3 cell lines were carried out. Since the growth of the BaF3 cell depends on the 
presence of IL-3, autonomous growth in the absence of IL-3 can be attributed to the presence of a 
transforming oncogene. Furthermore, being associated with the IL-3 receptor, the wild type JAK2 
kinase plays a vital role in the transduction of the pro-proliferative signal. Therefore, we speculated 
that a mutant, autonomously active JAK2 would continuously trigger the downstream pathway and 
promote proliferation, even in the absence of the otherwise obligatory growth factor. 
In order to compare the behaviour of native BaF3 cells, cells carrying the empty vector-DNA and cells 
expressing the fusion gene (Subsequently referred to as “Native, pMIG and BCR/JAK2”, respectively) 
in the presence and the absence of IL-3, the following experiment was set up: The three cultures 
were harvested and washed by three cycles of centrifugation and resuspension with DPBS to remove 
any IL-3 originating from WEHI medium. Simultaneously, two aliquots of RPMI medium containing 
10% FBS and 1% penicillin/streptomycin solution were prepared. To one of these aliquots, 10ng/ml 
of recombinant murine IL-3 (rm IL-3) was added. Native, pMIG and BCR/JAK2 cells were counted and 
subsequently suspended in culture medium with- and without IL-3. In total, six 6ml aliquots, each 
containing 180.000 cells were prepared and distributed between four 6-well plates. Finally, each cell 
line was represented by six wells: Three wells, each containing 80.000 cells suspended in 2ml 
medium with IL-3, and three wells containing 80.000 cells in 2ml medium without IL-3. The basic 
pattern of the experiment is shown in Figure 2: 
 
Figure 2: Set-up of the proliferation assay. The figure shows the distribution of 2ml cultures of the three BaF3 
lines “Native, pMIG and BCR/JAK2 (B/J2)” between four 6-well plates. 
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Except for the time required to obtain samples for counting, the 6-well plates were kept in an 
incubator at 37°C. 24 hours after the assay had been set up, a cell count of each well was obtained 
using a Neubauer counting chamber. Again, the samples were diluted and stained with trypan blue at 
two different ratios, and the average of both counts was used to calculate the number of cells per ml. 
Dead or dying cells, recognizable by their irregular shape and high uptake of trypan blue, were 
excluded from the count. For the first proliferation assay, cultures were counted six times, with the 
last count being performed 144 hours after the experiment was started. 
The second proliferation assay, while performed in a similar fashion, was carried out using BaF3 
BCR/JAK2 cells from the first assay, which were still vital and expanding despite the prolonged 
absence of IL-3. The aim of the second assay was to compare the cytokine-mediated proliferation 
activity of native cells, to the autonomous IL-3-independent proliferation of the transduced BaF3 line. 
The set-up of the second assay was identical, distributing Native, pMIG and BCR/JAK2 cell cultures 
between four 6-well plates. This time, the last cell count was obtained at 96 hours. 
 
2.2.4 Protein biochemistry 
 
2.2.4.1 Protein extraction from mammalian cells 
BaF3 cells transduced with the pMIG retroviral vector carrying the BCR/JAK2 fusion gene were 
harvested by centrifugation and washed twice by resuspension with PBS and subsequent 
centrifugation. The proteins were extracted using Quiagen’s Qproteome Mammalian Protein Prep Kit 
utilizing the buffers and solutions included in the kit and following the instructions provided by the 
manual. The protein samples were stored at -80°C for further use. 
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2.2.4.2 Western blot analysis 
To determine the presence of the BCR/JAK2 fusion protein, the protein extracts of stably transduced 
BaF3 cells as well as native BaF3 cells were examined. Standard Western blot analyses were 
performed using the SDS polyacrylamide gel electrophoresis method, closely following a well-
established protocol. An electric potential of 110V was applied until the stained bands of the protein 
ladder, which served as a scale on the separating gel, had travelled a satisfactory distance. The 
proteins were then transferred to a polyvinylidene pluoride (PVDF) membrane by electroblotting, 
applying an electric potential of 48V for 180 or 240 minutes. The next day, the membrane was 
incubated with the primary and secondary antibody. The JAK2 (D2E12)XP® Rabbit mAb, intended to 
bind the JAK2-rest of the fusion protein was the primary, the peroxidase-linked α Rabbit igG was the 
secondary antibody, intended to bind and later stain the first one. The membrane was treated with 
peroxidase and enhancer solution from the Super Signal West Pico Chemiluminescent Substrate Kit, 
photographic developer solution was added and the membrane and photographic film paper were 
placed together in an appropriate box for 15, 30 and 45 minutes, successively. 
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3 Results 
 
3.1 Cloning the BCR/JAK2 expression construct 
 
3.11 Development of a cloning strategy 
The cloning strategy was based on the availability of DNA fragments from three different sources: 
The BCR/JAK2 breakpoint fragment, derived from the patient sample, and two pcDNA3 plasmids, one 
containing BCR/ABL, the other one ETV6/JAK2. The BCR/JAK2 sequence published by Griesinger et al. 
served as a template for the planning, as well as the validation of the cloning process. 
Starting from the 358bp breakpoint fragment (BP), the 5‘ part of BCR and the 3‘ part of JAK2 had to 
be attached to its 5’ and 3’ ends in order to recreate the fusion gene (Figure 3). After identifying 
cutting sites for restriction enzymes within the BP fragment and the respective plasmids, it became 
clear that the BamH1 cutting site in the pcr2.1 polylinker region had to be eliminated prior to the 
other cloning steps. Similarly, a BsmB1 site in pcDNA3 BCR/ABL had to be cut out using Sac2 and 
Nse1, before the 3’ part of the BCR/JAK2 fusion gene could be cloned into the plasmid. During the 
first step of the cloning process, the 358 bp BP fragment, which was amplified from patient cDNA by 
PCR, was cloned into the linearized pcr2.1 vector.  Then, the breakpoint fragment had to be cut out 
using EcoR1, and inserted into the modified pcr2.1 plasmid without the BamH1.  
During the second step, BamH1 and Not1 were used to cut out the 3‘ portion of JAK2 from the 
pcDNA3 ETV6/JAK2 plasmid, and this 944 bp fragment was inserted into pcr2.1, thus completing the 
3’ part of the fusion gene.  
For the third step, a fragment of 1030 bp, spanning a short part of BCR close to the breakpoint, as 
well as the 3’ end of JAK2, was cut out of pcr2.1 using BsmB1 and Not1. It was subsequently cloned 
into the modified pcDNA3 BCR/ABL plasmid (after the removal of a second BsmB1 site located 5’ of 
BCR).   
For the final cloning step, the full length fusion gene was released from pcr2.1-BCR/JAK2 using EcoR1 
and cloned into the pMIG retroviral vector prior to the transfection of mammalian cells. Figure 3 
shows an overview of the cloning strategy. 
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Figure 3: Cloning strategy for the BCR/JAK2 fusion gene. BCR is pictured in yellow- JAk2 is pictured in blue colour. 
Starting with the 358bp BP fragment amplified by PCR, this figure illustrates the steps used to clone the complete 
BCR/JAK2 fusion gene. The final construct, pMIG BCR/JAK2, was used for the transfection of the murine BaF3 cell line, in 
order to perform a functional characterisation of the BRR/JAK2 gene. 
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3.12 Cloning process 
After the BamH1 site of pcr2.1 had been removed (see 2.2.2.8), the BP fragment was successfully 
cloned into a linearized pcr2.1 vector (see 2.2.2.6). Figure 4 shows the vector and the 358bp insert 
visualized after digestion with EcoR1. After that, the plasmid was again digested using EcoR1, the 
358bp insert was isolated by agarose gel electrophoresis (see 2.2.2.5) and inserted into the pcr2.1 
vector from which the BamH1 site had been removed. Since two EcoR1 sites meant that the 
breakpoint fragment could be inserted in two different orientations, the plasmids containing the 
inserts in the correct orientation had to be identified.  This was done by control digestions with 
different restriction enzymes and the visualisation of the resulting DNA fragments by agarose gel 
electrophoresis. Figure 5 depicts the result of two control digestions performed with plasmids 
obtained from several E. coli DH5α colonies after transformation with the ligation reaction.  
For the next step, the pcDNA3 ETV6/JAK2 plasmid was digested using BamH1 and Not1, and a 944bp 
fragment corresponding to the 3’ portion of the JAK2 coding region was isolated. The pcr2.1 vector 
containing the BP fragment was also cut with BamH1 and Not1, and a big fragment containing the 
vector and the BP fragment up to the BamH1 site was gel purified. The 3’ JAK2 fragment was then 
cloned into the pcr2.1 vector with the BP fragment, completing the JAK2 part of the fusion gene. 
Figure 6 shows a control digestion of plasmids derived from 8 E. coli DH5α colonies after 
transformation, using EcoR1 and Not1 to determine the correct length of the insert. After the 
successful ligation had been validated by a series of control digestions, the bulk of the insert, 
spanning from within the BCR segment of the breakpoint region to the 3’ end of JAK2, was cut out 
using BsmB1 and Not1, and ligated with the modified pcDNA3 BCR/ABL plasmid (one BsmB1 site 
removed) after digestion with BsmB1 and Not1. This plasmid had been digested with Sac2 and Nse1, 
blunted and religated, eliminating one of the BsmB1 sites. By digestion with BsmB1 and Not1, a large 
section containing the ABL part of the fusion gene, had been removed – allowing the insertion of the 
BP fragment and the 3’ end of JAK2. Figure 7 shows the new insert of 2294 bp, consisting of the 
BCR/JAK2 fusion gene after digestion with EcoR1. The insert was then sequenced using the “BCR 
forward”, “JAK2 reverse” and “pcDNA3 reverse” primers to confirm the integrity of the expression 
construct (see 2.2.2.10). 
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Figure 4: The pcr2.1 plasmid and the 358bp insert containing the BCR/JAK2 breakpoint fragment, visualized by 
agarose gel electrophoresis after digestion with EcoR1 (Lane 1). The uncut plasmid (lane 2) is supercoiled and 
migrates a little faster than the linearized vector.  
 
 
Figure 5: Agarose gel electrophoresis: Control digestions performed with plasmids obtained from several E. coli 
DH5α colonies after transformation with the BamH1-depleted pcr2.1 plasmid ligated with the breakpoint 
fragment. The upper image shows plasmids extracted from 12 different E. coli DH5α colonies cut with BamH1 
and Not1. The correct orientation of the insert, indicated by the presence of a 128 bp fragment, can be seen in 
most plasmids. However, the wrong orientation, indicated by a 284 bp fragment (white arrow), can be 
observed in three of the samples. The lower image shows the presence of the BCR/JAK2 breakpoint fragment in 
all of the plasmids with the correctly oriented insert. 
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Figure 6: Agarose gel electrophoresis of plasmids obtained from 8 different E. coli DH5α colonies after digestion 
with EcoR1 and Not1. A correct insert length of 1211bp can only be observed in the second sample (indicated 
by the white arrow). Further confirmation of the integrity of the insert was performed, but is not shown here. 
 
Figure 7: Agarose gel electrophoresis: Control digestion of pcDNA3 BCR/ABL with EcoR1. The 2294bp insert 
containing the complete BCR/JAK2 fusion gene can be seen in three plasmid samples extracted from E. coli 
XL10-gold colonies after transformation. 
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For the last cloning step, the complete BCR/JAK2 insert was cut out using EcoR1, and ligated with the 
pMIG vector, which was linearized by EcoR1 digestion as well. Again, the possibility of two different 
orientations required a control experiment designed to distinguish both variants. Figure 8 depicts an 
agarose gel electrophoresis of a control digestion with Xho1 performed with plasmids obtained from 
7 different E. coli DH5α colonies after transformation. Prior to the transduction of mammalian cells, 
the plasmid was again sequenced using the “BCR forward”, “JAK2 reverse”, “pMIG forward” and 
“pMIG reverse” primers, confirming the integrity of the fusion gene within the retroviral vector (see 
2.2.2.10). The complete sequence can be found in the Appendix section. 
 
 
Figure 8: Agarose gel electrophoresis: Control digestion of 7 plasmid samples extracted from 7 different E. coli 
DH5α colonies using Xho1. A correctly oriented insert is indicated by the presence of a 1652bp fragment, which 
is visible in 6 out of 7 samples. This result was rather unexpected, since the probability of both orientations 
should be at 50% each. 
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3.2 BCR/JAK2 induces IL-3 independent growth of BaF3 cells in vitro 
 
In order to produce stably transduced cell lines of BaF3 cells, retroviral particles containing the 
BCR/JAK2 fusion gene in the pMIG vector, as well as retroviral particles containing the empty pMIG 
vector, were generated by transfection of the Phoenix-ECO cell line using the CaPO₄ precipitation 
method (see 2.2.3.4 and 2.2.3.5). The virally conditioned medium (VCM) was harvested and used for 
the transduction of BaF3 cells (see 2.2.3.6). Initially, flow cytometry revealed a very low transduction 
efficiency:  At the time of the first FACS sorting, as little as 0.14% of cells transduced with pMIG-
BCR/JAK2, and only 0.75% of cells transduced with the empty pMIG vector were GFP positive. This 
rate was then increased by repeated sorting (See 2.2.3.8). After a total of three rounds of FACS 
sorting, the proportion of GFP positive cells was > 98% in both transduced cell lines (BaF3 pMIG, BaF3 
pMIG-BCR/JAK2). 
After stably transduced cell lines had been established, the first proliferation assay was carried out as 
described in 2.2.3.9. The assay revealed an overwhelming advantage for BCR/JAK2 tansduced and 
expressing cells over the native and empty vector transduced cell lines in the absence of IL-3. In the 
presence of 10ng/ml IL-3, the three cell lines did not exhibit any major differences in proliferation. 
However, in the wells containing IL-3-free medium, the picture was different: After 24 hours, the 
proliferation of all three cell lines was stagnating. 24 hours later, the number of dead cells, 
identifiable by intense staining and irregular shape, had increased significantly in all three cell lines. 
From 48 hours onwards, a difference between the BaF3 line transduced with the BCR/JAK2 retroviral 
construct and the native and empty vector transduced lines could be observed. While a fraction of 
the BaF3 pMIG-BCR/JAK2 cells was dying, another fraction was expanding, and the overall number of 
cells began to increase. When the assay was stopped at 144 hours, The BCR/JAK2 transduced cell line 
was rapidly expanding, while living cells were only sporadically observed within the native and empty 
vector transduced lines. Figure 9 depicts the growth of the three BaF3 cell lines (Native, pMIG and 
BCR/JAK2 transduced) in the presence ofIL-3. Figure 10 depicts the growth of the three BaF3 cell lines 
(Native, pMIG and BCR/JAK2 transduced) in the absence ofIL-3. 
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Figure 9: 1st proliferation assay: Growth of the three cell lines “Native, pMIG and BCR/JAK2 (B/J2)” over time in 
the presence of 10ng/ml IL-3. The graphs represent the mean value of the total number of cells from three 
independent cell culture wells, which were counted using a Neubauer counting chamber. Standard deviation is 
indicated by black bars. 
 
 
Figure 10: 1st proliferation assay: Growth of the three cell lines “Native, pMIG and BCR/JAK2” over time in the 
absence of IL-3. The graphs represent the mean value of the total number of cells from three independent cell 
culture wells, which were counted using a Neubauer counting chamber. Standard deviation is indicated by 
black bars. 
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The second proliferation assay, which was primarily intended to compare the IL-3-dependent and 
independent growth of the stably transduced BaF3 pMIG-BCR/JAK2 cell line, yielded similar results. 
This time however, the pre-selected BCR/JAK2 cells expanded from the beginning. Figure 11 and 12 
depict the results of the second proliferation assay. 
 
 
Figure 11: 2nd proliferation assay: Growth of the three cell lines “Native, pMIG and (pre-selected) BCR/JAK2 
(B/J2)” over time in the presence of 10ng/ml IL-3. The graphs represent the mean value of the total number of 
cells from three independent cell culture wells, which were counted using a Neubauer counting chamber. 
Standard deviation is indicated by black bars. 
 
 
Figure 12: 2nd proliferation assay: Growth of the three cell lines “Native, pMIG and (pre-selected) BCR/JAK2” 
over time in the absence of IL-3. The graphs represent the mean value of the total number of cells from three 
independent cell culture wells, which were counted using a Neubauer counting chamber. Standard deviation is 
indicated by black bars. 
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Generally, the proliferation assays strongly support the assumption, that the presence of the 
BCR/JAK2 fusion gene promotes growth-factor independent cell proliferation. In the absence of IL-3, 
BaF3 cells containing the gene had a strong growth advantage over the native, as well as the empty 
vector cell line. 
3.21 IL-3 independent proliferation is weaker than IL-3 dependent growth in vitro 
When directly comparing the BaF3 pMIG-BCR/JAK2 cell line in terms of IL-3 mediated and IL-3 
independent proliferation, the growth-factor independent growth was shown to be significantly 
weaker. At 96 hours, the average number of cells per ml was 1.7792x10⁶ in the wells without IL-3, 
and 2.8042x10⁶ in the wells containing the growth factor. A graph illustrating the growth of the 
BCR/JAK2 transduced BaF3 cell line under different conditions is shown in figure 13.  
 
 
Figure 13: 2nd proliferation assay: Comparison of pre-selected BaF3 pMIG-BCR/JAK2 cells with- and without 
10ng/ml IL-3. The graphs represent the mean value of the total number of cells from three independent cell 
culture wells, which were counted using a Neubauer counting chamber. Standard deviation is indicated by 
black bars. 
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limits. On the other hand, cell proliferation in IL-3 free medium is most likely linked to- and limited 
by- the expression of the BCR/JAK2 fusion gene and the activity of the corresponding protein. 
Additionally, the BaF3 cells, an immortalized murine B-cell precursor cell line, are not comparable to 
normal lymphocytes in terms of proliferation, resistance to apoptosis etc.. Although a comparison of 
receptor-mediated and autonomous growth can be made in vitro, the results should not lead to any 
conclusions regarding the in vivo proliferation of hematopoitic cells expressing a BCR/JAK2 fusion 
gene in vivo. 
 
3.22 Validation of the fusion gene in retrovirally transduced BaF3 cells by PCR 
A PCR using the 5’ BCR sense primer and 3’ JAK2 antisense primer (see 2.1.12) was carried out in 
order to validate the presence of the fusion gene in the stably transduced BaF3 pMIG-BCR/JAK2 cell 
line. The characteristic 358 bp amplification product was then visualized by agarose gel 
electrophoresis, confirming the presence of BCR/JAK2 fusion transcripts in the cells. Figure 14 shows 
the BCR/JAK2 breakpoint fragment after PCR amplification visualized by agarose gel electrophoresis. 
 
 
Figure 14:   
Left picture: PCR of the cDNA patient sample, visualized by agarose gel electrophoresis. The 358 bp BCR/JAK2 
breakpoint fragment (1) can be seen next to the 80-1000 bp ladder, and the PCR control (2). 
Right picture: PCR of genomic DNA extracted from BaF3 cells of the second proliferation assay. The breakpoint 
fragment can be seen in the lane containing a PCR sample from the BaF3 pMIG-BCR/JAK2 cells (B/J2). 
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3.23 Western blot analysis 
Despite several attempts, it was not possible to confirm the presence of the BCR/JAK2 fusion protein 
by Western blot analysis (see 2.2.4.2). Although the first antibody, a monoclonal JAK2 antibody, 
targets residues surrounding Pro841 of the JAK2 protein (see Figure 1), a section of JAK2 which 
should be present in the BCR/JAK2 fusion, neither the normal JAK2 protein, nor the mutated 
BCR/JAK2 fusion protein could be detected. Most likely, successful detection of these two proteins 
would have been a matter of time and refinement of the Western blotting technique. However, 
towards the end of the project, time was running short for various reasons and work on the Western 
blot analysis was discontinued. It is worth ot mention that another group conducting similar 
experiments involving a retroviral expression model of this particular BRC/JAK2 variant in the BaF3 
cell line was able to show Western blots of both the normal JAK2 protein of ~130 kDa, as well as the 
BCR/JAK2 fusion protein of ~90 kDa (Cuesta-Domínguez et al., 2012). 
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4 Discussion 
 
4.1 The BCR/JAK2 fusion gene 
 
4.11 Functional characterisation 
According to the current model, the BCR/JAK2 fusion gene combines two key features of the BCR and 
the JAK2 genes: The first one is the N-terminal coiled-coil dimerisation domain of BCR, an α2 helix 
superstructure capable of forming an antiparallel coiled-coil with the corresponding domain of 
another BCR protein, which is the basis of the formation of dimers and tetramers (Zhao et al., 2002). 
The second one, the JH1 domain of JAK2, has two lobes - an N-terminal lobe, containing a twisted β-
sheet and an α-helix superstructure, and a C-terminal lobe containing several α-helices - in between 
of which the catalytic activity of the tyrosine kinase is thought to be located (Lindauer et al.,2001). 
Since it is believed that receptor-bound JAKs usually activate each other by cross-phosphorylation 
after dimerisation of cytokine receptors (Wagner C, Müller O, 2010), it is very likely that this 
mechanism also operates in the BCR/JAK2 fusion protein after di- or tetramerisation mediated by the 
coiled-coil dimerisation domain of the BCR portion.  
 
Figure 15: Diagram of the BCR/JAK2 (BCR exon 1, JAK2 exon 19) fusion protein according to Griesinger et al., 
indicating the positions of the N-terminal coiled-coil dimerisation domain of BCR (CC), and the JH1 tyrosine 
kinase domain of JAK2 (JH1) (Griesinger et al., 2005). 
 
Presumably, the downstream pathways activated by the fusion protein are very similar to those 
activated by wild type JAK2, phosphorylating STAT1, 3, 4 and 5 proteins which, once activated, act as 
transcription factors for a number of genes (see table 1). Of these transcription factors, only STAT5 is 
activated solely by JAK2, and it is therefore a likely target of the BCR/JAK2 kinase. While activated 
STAT5 monomers can shuttle between nucleus and cytoplasm, STAT5 dimers are actively transported 
to and retained inside the nucleus (Basham et al., 2008). Interestingly, a mutant, constitutively 
activated STAT5 protein alone was shown to induce growth factor-independent proliferation in Ba/F3 
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cells in vitro (Nosaka et al., 1999). The transcriptional targets of STAT5 include Pim-1 (Proto-
oncogene serine/threonine-protein kinase) and Bcl-xl (B-cell lymphoma-extra large), which may both 
have tumorigenic potential. The Pim-1 serine/threonine kinase, which is overexpressed in 
hematopoietic malignancies and prostate cancer, is able to phosphorylate several proteins involved 
in cell cycle progression and apoptosis (Bachmann et al., 2005). Bcl-xl, which is a member of the Bcl-2 
family, prevents the activation of downstream effector caspases by blocking the release of 
cytochrome C from mitochondria, thereby providing some resistance to apoptosis (Shimizu et al., 
2000, Tsujimoto et al., 2000). Considering these findings, our working theory for the cell culture 
experiments can be summarized as follows: The BCR coiled-coil domain mediated dimerization of the 
BCR/JAK2 fusion protein results in consitutive activation of the JAK2/STAT pathway, leading to 
enhanced cell proliferation and survival – in this case, the IL-3 independent survival of BaF3 cells. 
It is worth to note that our results correspond well with the data published by Cuesta-Domínguez et 
al. (Cuesta-Domínguez et al., 2012). Here, BaF3 cells were transduced with a similar BCR/JAK2 variant 
derived from a 58-year-old male patient diagnosed with ALL. The proliferation assays performed by 
this group revealed a significant advantage for the transduced cell line over the native BaF3 cell line 
in the absence of IL-3. Elevated levels of phosphorylated STAT5 were reported in native BaF3 cells in 
the presence of IL-3, as well as in BCR/JAK2 transduced BaF3 cells in the absence of IL-3, supporting 
the assumption that STAT5 is an important substrate of the BCR/JAK2 tyrosine kinase. Accordingly, 
qPCR of the Bcl-xl gene expression revealed an increased expression of Bcl-xl by a factor of two to 
three. However, the results of the proliferation assays presented in this doctoral thesis and by 
Cuesta-Domínguez et al. differ slightly in one aspect – while BaF3 cells carrying the fusion gene seem 
to exhibit a very similar proliferation rate with- and without 10ng/μl IL-3 in the data shown by 
Cuesta-Domínguez et al., our assays suggest a significant advantage of cytokine-dependent BaF3 
proliferation over the cytokine-independent proliferation mediated by the BCR/JAK2 fusion protein 
(see 3.11). 
Going back further, in 1999, Liu et al. published data from proliferation assays showing proliferation 
and increased survivability in BaF3 cells, transduced with a chimeric JAK2 construct, in the absence of 
murine IL-3 (Liu et al., 1999). A chimeric, constitutively active (βc/JAK2) molecule combining the βc 
subunit of the GM-CSF receptor with the JAK2 tyrosine kinase, was utilized to induce cytokine-
independent BaF3 proliferation very similar to the data presented by Cuesta-Domínguez et al., as 
well as in this doctoral thesis. This βc subunit, which is also present in the receptors for IL-3 and IL-5, 
is capable of dimerisation, much like the coiled-coil dimerisation domain of BCR.Additionally, Liu et al. 
reported that the level of proliferation of transduced BaF3 cells without IL-3 was less than the level of 
proliferation observed in the presence of up to 10ng/ml IL-3.  
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Of course, the induction of factor-independent proliferation of BaF3 cells cannot be interpreted as 
direct proof of the tumorigenic properties of the BCR/JAK2 fusion gene. Firstly, the immortalized 
BaF3 murine pro B cell line is already a tumour cell line, which is often used as a model for- but does 
not completely match- the biology of normal murine lymphocytes. Secondly, in vitro models like the 
one used in this doctoral thesis are, per se, flawed by the absence of a cellular environment similar to 
a living body, in which a disease involving this gene would develop. This environment provides a 
multitude of cytokines and chemokines as well as the host’s immune system trying to eliminate 
developing tumours. An experimental animal model for lymphatic tumours, which takes these factors 
into account, would – for example - have to include the transduction of murine bone marrow cells 
with a retroviral vector carrying BCR/JAK2, which would then be transplanted back into recipient 
mice. This way, it would be possible to observe the development of a malignant haematological 
disease in mice, assuming that the isolated presence of a BCR/JAK2 fusion gene would be sufficient 
to drive tumorigenesis. Despite solving many problems, such a model would still rely on a retroviral 
expression construct like pMIG, which features a constitutively active viral promoter instead of the 
physiological promoter of BCR, which would normally regulate the expression of a BCR/JAK2 fusion 
gene originating from a t(9;22)(p24;q11.2). It is possible that besides the BCR/JAK2 fusion, additional 
mutations need to be acquired prior to the onset of a full-blown malignant disease. However, this 
crucial question cannot be answered based on the data presented in this doctoral thesis. 
 
4.2 Clinical aspects 
 
4.21 Possible implications for diagnostics 
It is highly interesting that the BCR/JAK2 fusion has been reported in conjunction with a broad 
spectrum of haematological diseases involving the myeloid, as well as the lymphoid lineage. These 
include CML, AML, ALL and an unclassifiable myeloproliferative neoplasm/MPN (see 1.24 and Table 
4). The occurrence of BCR/JAK2 in both CML like malignancies and lymphoid acute leukaemia is 
strikingly similar to the BCR/ABL translocation which can also be found both in CML and ALL and 
sometimes AML (Kurzrock et al., 1987). As mentioned before, activating mutations of JAK2 can 
induce other malignancies, such as the ETV6/JAK2 fusion in ALL or the JAK2V617F mutation in 
Polycythaemia Vera (see 1.25). Although only a limited number of case reports describing the 
BCR/JAK2 fusion gene in haematopoietic diseases have been published to date (A total of nine cases 
have been published as of 03/2015), the actual incidence might be higher than the rarity of 
publications suggests. It is unlikely that a t(9;22)(p24;q11.2), which results in the BCR/JAK2 fusion, 
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can be mistaken for the  well known t(9;22)(q34;q11.2) translocation in a CML like disease. However, 
in cases with a lymphoid phenotype a t(9;22)(p24;q11.2) could be hiding in a complex karyotype and 
be overlooked in some instances. FISH analysis with BCR and ABL1 probes, which is frequently 
performed in such cases, would show three signals for BCR, but only two signals for ABL1, indicating 
intact ABL alleles and therefore suggesting another fusion involving BCR. 
Since the t(9;22)(p24;q11.2) does not lead to the formation of a BCR/ABL1 fusion protein, the disease 
will not respond to Imatinib or similar TKIs targeting ABL, leading to the administration of ineffective 
medication if diagnostics are limited to conventional cytogenetics or the wrong conclusions are 
drawn. In the case reports mentioned in 1.24, the atypical translocation was usually found by PCR, 
using different pairs of BCR forward and JAK2 reverse primers, and sequencing. During the 
experimental work for this publication, PCR amplification of a 358 bp BCR/JAK2 breakpoint fragment, 
as initially described by Griesinger et al., was used as a fast and reliable method to confirm the 
presence of the BCR/JAK2 fusion gene (see 2.2.2.9).  
For clinicians and diagnosticians, awareness of the possibility of rare genomic alterations may be the 
key to detecting cases of uncommon translocations in haematopoietic diseases. In some cases, the 
perceived presence of the Philadelphia chromosome led to the administration of ABL kinase 
inhibitors over an extended period of time in BCR/ABL negative diseases (Griesinger et al., 2005; 
Impera et al., 2011; Bellesso et al., 2013). Since the BCR/JAK2 fusion is easily detectable by PCR when 
actively searched for, the appropriate testing should be performed to confirm its presence in the 
rather uncommon case of a Ph+, but ABL1 kinase inhibitor-resistant disease. 
 
4.22 Possible clinical applications in therapy 
Since JAK2-specific tyrosine kinase inhibitors have been approved by the US Food and Drug 
Administration for the treatment of intermediate and high-risk myelofibrosis, primary myelofibrosis, 
post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis, the use 
of these JAK1/JAK2 inhibitor in the case of a BCR/JAK2 positive disease is currently limited to clinical 
trials or off-label use (Mesa et al., 2012). Recently, a publication by Schwaab et al. described clinical 
data of a patient diagnosed with a BCR/JAK2 positive myeloproliferative neoplasm (MPN) treated 
with Ruxolitinib (Schwaab et al., 2014). TKI treatment was initially effective, achieving a complete 
haematologic response after 6 months and a complete cytogenetic response after 12 months, 
although the fusion gene was still detectable by PCR analysis. The patient suffered a relapse 18 
months after the start of Ruxolitinib treatment and ultimately underwent allogeneic stem cell 
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transplantation. Nevertheless, Schwaab et al. could demonstrate clinical effectiveness of a JAK1/JAK2 
inhibitor in a patient suffering from a haematologic disease with a BCR/JAK2 fusion gene.  
Besides Ruxolitinib, several selective inhibitors of JAK2, like NS-018, BMS-911543, LY2784544, 
SB1518 and SAR302503/TG101348 are currently undergoing pre-clinical testing or clinical trials 
(Younes et al., 2012; Purandare et al., 2012; Ma et al., 2013; Zhang et al., 2014; Nakaya et al., 2014). 
Such developments will likely lead to the introduction of new, more selective JAK2 inhibitors, and the 
clinical use of these substances in the broad spectrum of JAK2 driven haematological malignancies. 
These trials will hopefully provide the data needed to determine which JAK2 inhibitors are 
appropriate for patients suffering from diseases driven by a BCR/JAK2 fusion gene.  
  
 65 
5 Conclusion 
Research in the field of cancer biology has rapidly accelerated over the past twenty years, revealing 
new details about the genetics and molecular pathways associated with a multitude of malignancies. 
Few things might underline the importance of basic research more impressively than the 
development of new drugs for the treatment of cancer, such as the advent of targeted therapies as 
exemplified by the development of the ABL tyrosine kinase inhibitor Imantinib for the treatment of 
BCR/ABL-positive malignancies, espcially CML. This development led to a significant improvement of 
the prognosis of patients diagnosed with BCR/ABL positive leukaemia (Drucker et al., 1996, Drucker 
et al., 2006). The discovery and characterisation of chromosomal translocations and the resulting 
tumorigenic mutations, as the description of the BCR/JAK2 fusion gene, contributes to the 
development of more specific, individualized therapies.  
The approach of this doctoral thesis was to establish a stable in vitro model and to demonstrate the 
pro-proliferative effects of the BCR/JAK2 fusion. This aim was successfully achieved as the fusion 
gene triggered strong, growth factor independent proliferation in BaF3 cells after retroviral 
transduction, which differed significantly from the cell line’s growth factor-dependent proliferation. 
Although additional experiments, like the further characterisation of downstream pathways, or the 
development of a BCR/JAK2 bone marrow transplantation model were not possible, mostly due to 
logistical limitations and time restriction, the work will hopefully contribute to the ongoing effort to 
better understand this particular fusion gene, i.e. to provide accurate data regarding the proliferation 
of transduced BaF3 cells, to validate results published by other groups and to draw attention towards 
the occurrence of the BCR/JAK2 fusion in haematological diseases.  
As a growing number of case reports with the BCR/JAK2 fusion gene have been published in recent 
years, and the first clinical attempt to administer an inhibitor of JAK2 to a patient diagnosed with 
BCR/JAK2 positive MPN has been made, more reports on this subject are likely to follow. The data 
collected by clinicians will help to improve treatment for these patients, and the continued 
development of targeted therapies, such as novel tyrosine kinase inhibitors, will likely contribute to 
this trend. Although basic as well as clinical research is often perceived to be rather slow and difficult, 
continuous advances in the field of malignant diseases have significantly improved the overall 
prognosis of cancer patients over the course of only a few decades.  
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6 Zusammenfassung 
Auf dem Gebiet der Tumorbiologie wurden Im Verlauf der letzten zwei Jahrzehnte bedeutende 
Fortschritte gemacht, die zum Verständnis der molekularen Signalwege und genetischen Grundlagen 
einer Vielzahl von Tumorerkrankungen beitrugen. Dabei gibt es kaum bessere Beispiele für die 
Wichtigkeit medizinischer Grundlagenforschung als die Entwicklung von Pharmaka zur Krebstherapie, 
welche gegen molekulare Zielstrukturen der Tumorzelle gerichtet sind. So hat die Entwicklung von 
Imatinib, einem Inhibitor der ABL-Tyrosinkinase zur Behandlung BCR/ABL-positiver Leukämien wie 
der CML, zu einer deutlichen Verbesserung der Prognose der betroffenen Patienten geführt (Drucker 
et al., 1996, Drucker et al., 2006). Dementsprechend trägt die Identifikation und Charakterisierung 
chromosomaler Translokationen und der daraus resultierender Mutationen mit onkogenem Potential, 
wie die Beschreibung des BCR/JAK2 Fusionsgens, entscheidend zur Entwicklung neuer, spezifischerer 
Therapiestrategien für diese Patienten bei.  
Ziel der experimentellen Arbeit zur Dissertation war die Klonierung des BCR/JAK2 Fusionsgens und 
die Etablierung eines stabilen in vitro-Modells zur Demonstration eines pro-proliferativen Effekts. 
Dieses Ziel wurde erreicht - wobei letztendlich sowohl die Zeit, als auch die nötigen Ressourcen für 
weitere Experimente wie der Untersuchung der assoziierten Signalwege, oder der Etablierung eines 
Tiermodells für BCR/JAK2-getriebene Leukämien, fehlten. Dennoch konnte gezeigt werden, dass das 
mittels eines retroviralen Vectors in BaF3 Zellen eingebrachte BCR/JAK2 Fusionsgen zu einer 
Wachstumsfaktor-unabhängigen Proliferation dieser Zellen führt, welche sich vom Wachstumsfaktur-
abhängigen Proliferationsverhalten signifikant unterscheidet. Durch die Veröffentlichung von 
Referenzdaten zum Proliferationsverhalten mit BCR/JAK2 transduzierter lymphatischer Zellen sowie 
der Validation der Ergebnisse anderer Gruppen, soll die hier präsentierte Arbeit zum Verständnis 
dieses speziellen Fusionsgens beitragen und zudem auf eine seltene, aber hochinteressante 
chromosomale Translokation mit therapierelevanten Konsequenzen hinweisen. 
Da in letzter Zeit eine kleine, aber wachsende Zahl an Berichten BCR/JAK2 positiver hämatologischer 
Erkrankungen, sowie der erste klinische Therapieversuch mit einem JAK2-spezifischen 
Tyrosinkinaseinhibitor veröffentlicht wurde, ist es wahrscheinlich, dass in den nächsten Jahren 
weitere Veröffentlichungen zu diesem Thema folgen werden. Die darin enthaltenen klinischen und 
experimentellen Daten werden, in Verbindung mit der Entwicklung neuerer Tyrosinkinaseinhibitoren, 
dazu beitragen die Behandlung dieser Patienten zu verbessern. Obwohl Fortschritte im Bereich der 
Tumor- und molekularbiologischen Grundlagenforschung langsam und umständlich erscheinen 
können, haben stetige Fortschritte in diesen Bereichen die Prognose von Krebspatienten innerhalb 
weniger Jahrzehnte dramatisch verbessert. 
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Appendix 
 
Appendix I: Sequence of the BCR/JAK2 fusion in pcDNA3 
 
 
Figure 16: Vector map of the BCR/JAK2 fusion gene within the pcDNA3 plasmid. The 5’ BCR and the 3’ JAK2 
sections of the 2241 BP fusion gene are highlighted in yellow and blue, respectively. A single nucleotide 
polymorphism is highlighted in red colour. 
 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGG
AGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCT
GCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGA
GTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCC
AATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGA
CGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACC
ATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTT
TTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGC
AGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTGGTACCGAGCTCGGATCCA
CTAGTAACGGCCGCCAGTGTGCTGGAATTCCGCGGGGCCATGGGGGCCGCCCGGCGCCCGGGGCCGGGCCTGGCGAGGCCGCCGCGCCGCCGCTGAGA
CGGGCCCCGCGCGCAGCCCGGCGGCGCAGGTAAGGCCGGCCGCGCCATGGTGGACCCGGTGGGCTTCGCGGAGGCGTGGAAGG
CGCAGTTCCCGGACTCAGAGCCCCCGCGCATGGAGCTGCGCTCAGTGGGCGACATCGAGCAGGAGCTGGAGC
GCTGCAAGGCCTCCATTCGGCGCCTGGAGCAGGAGGTGAACCAGGAGCGCTTCCGCATGATCTACCTGCAGA
CGTTGCTGGCCAAGGAAAAGAAGAGCTATGACCGGCAGCGATGGGGCTTCCGGCGCGCGGCGCAGGCCCCC
 72 
GACGGCGCCTCCGAGCCCCGAGCGTCCGCGTCGCGCCCGCAGCCAGCGCCCGCCGACGGAGCCGACCCGCCG
CCCGCCGAGGAGCCCGAGGCCCGGCCCGACGGCGAGGGTTCTCCGGGTAAGGCCAGGCCCGGGACCGCCCG
CAGGCCCGGGGCAGCCGCGTCGGGGGAACGGGACGACCGGGGACCCCCCGCCAGCGTGGCGGCGCTCAGGT
CCAACTTCGAGCGGATCCGCAAGGGCCATGGCCAGCCCGGGGCGGACGCCGAGAAGCCCTTCTACGTGAACG
TCGAGTTTCACCACGAGCGCGGCCTGGTGAAGGTCAACGACAAAGAGGTGTCGGACCGCATCAGCTCCCTGG
GCAGCCAGGCCATGCAGATGGAGCGCAAAAAGTCCCAGCACGGCGCGGGCTCGAGCGTGGGGGATGCATCC
AGGCCCCCTTACCGGGGACGCTCCTCGGAGAGCAGCTGCGGCGTCGACGGCGACTACGAGGACGCCGAGTTG
AACCCCCGCTTCCTGAAGGACAACCTGATCGACGCCAATGGCGGTAGCAGGCCCCCTTGGCCGCCCCTGGAGT
ACCAGCCCTACCAGAGCATCTACGTCGGGGGCATGATGGAAGGGGAGGGCAAGGGCCCGCTCCTGCGCAGC
CAGAGCACCTCTGAGCAGGAGAAGCGCCTTACCTGGCCCCGCAGGTCCTACTCCCCCCGGAGTTTTGAGGATT
GCGGAGGCGGCTATACCCCGGACTGCAGCTCCAATGAGAACCTCACCTCCAGCGAGGAGGACTTCTCCTCTGG
CCAGTCCAGCCGCGTGTCCCCAAGCCCCACCACCTACCGCATGTTCCGGGACAAAAGCCGCTCTCCCTCGCAGA
ACTCGCAACAGTCCTTCGACAGCAGCAGTCCCCCCACGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGT
TGTCGTGTCCGAGGCCACCATCGTGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGC
CTTCCATGGAGACGCAGATTATGAACTATTAACAGAAAATGACATGTTACCAAATATGAGGATAGGTGCCCTG
GGGTTTTCTGGTGCCTTTGAAGACCGGGATCCTACACAGTTTGAAGAGAGACATTTGAAATTTCTACAGCAACT
TGGCAAGGGTAATTTTGGGAGTGTGGAGATGTGCCGGTATGACCCTCTACAGGACAACACTGGGGAGGTGGT
CGCTGTAAAAAAGCTTCAGCATAGTACTGAAGAGCACCTAAGAGACTTTGAAAGGGAAATTGAAATCCTGAAA
TCCCTACAGCATGACAACATTGTAAAGTACAAGGGAGTGTGCTACAGTGCTGGTCGGCGTAATCTAAAATTAA
TTATGGAATATTTACCATATGGAAGTTTACGAGACTATCTTCAAAAACATAAAGAACGGATAGATCACATAAAA
CTTCTGCAGTACACATCTCAGATATGCAAGGGTATGGAGTATCTTGGTACAAAAAGGTATATCCACAGGGATC
TGGCAACGAGAAATATATTGGTGGAGAACGAGAACAGAGTTAAAATTGGAGATTTTGGGTTAACCAAAGTCTT
GCCACAAGACAAAGAATACTATAAAGTAAAAGAACCTGGTGAAAGTCCCATATTCTGGTATGCTCCAGAATCA
CTGACAGAGAGCAAGTTTTCTGTGGCCTCAGATGTTTGGAGCTTTGGAGTGGTTCTGTATGAACTTTTCACATA
CATTGAGAAGAGTAAAAGTCCACCAGCGGAATTTATGCGTATGATTGGCAATGACAAACAAGGACAGATGAT
CGTGTTCCATTTGATAGAACTTTTGAAGAATAATGGAAGATTACCAAGACCAGATGGATGCCCAGATGAGATC
TATATGATCATGACAGAATGCTGGAACAATAATGTAAATCAACGCCCCTCCTTTAGGGATCTAGCTCTTCGAGT
GGATCAAATAAGGGATAACATGGCTGGAGAACAGAAGCTTATTTCAGAGGAAGACCTCTAGTCGAGAATTCTGCAGATATCCAGCACAG
TGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCC
ATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGT
AGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTAT
GGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAG
CGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGG
GCATCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACG
GTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATA
AGGGATTTTGGGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAATTCTGTGGAATGTGTGTCAGTTAGGGTGTGG
AAAGTCCCCAGGCTCCCCAGGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAG
AAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCC
 73 
CATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTT
TGCAAAAAGCTCCCGGGAGCTTGTATATCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGCAG
GTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGG
GCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCT
TGCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTG
CCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGA
GCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCG
CGCATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGG
CCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTT
TACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGGACTCTGGGGTTCGAAATGACCGACCAAGCGA
CGCCCAACCTGCCATCACGAGATTTCGATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTGGATGATCCTCCAGC
GCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAG
CATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTATACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGG
TCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAG
CTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCG
GTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATAC
GGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTT
TCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCT
GGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCT
GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTC
TTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT
GAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGAT
CCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCT
ACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATG
AAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCA
TCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACC
GGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCC
GGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCA
TTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAG
TTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCA
AGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCT
TTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCT
TCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCAC
ATTTCCCCGAAAAGTGCCACCTGACGTC 
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Appendix II: List of GMOs 
 
Organism Plasmid Produced Discarded 
E. coli DH5α pcDNA3 BCR-ABL 24.04.2012 31.07.2012 
E. coli DH5α pcDNA3 ETV6-JAK2 24.04.2012 31.07.2012 
E. coli DH5α pcr2.1 Vector 11.06.2012 14.09.2012 
E. coli DH5α pcr2.1 (minus BamH1 cutting site) 02.08.2012 14.09.2012 
E. coli DH5α pcr2.1 BCR-JAK2 breakpoint fragment 07.09.2012 17.12.2012 
E. coli DH5α pcDNA3 BCR-ABL (minus 5’ BsmB1) 06.11.2012 08.01.2013 
XL 10-Gold 
ultracompetent cells 
pcr2.1 BCR-JAK2 BCR(fragment)-JAK2(complete) 06.11.2012 08.01.2013 
XL 10-Gold 
ultracompetent cells 
pcDNA3(mod.)  BCR-JAK2  21.12.2012 01.02.2013 
E. coli DH5α pMIG Vector 23.01.2013 04.06.2013 
E. coli DH5α pMIG BCR-JAK2 31.01.2013 04.06.2013 
Ba/F3 murine lymphocyte 
cell line 
pMIG Vector 13.06.2013 - 
Ba/F3 murine lymphocyte 
cell line 
pMIG BCR-JAK2 13.06.2013 - 
Table 5: List of genetically modified organisms (GMOs). All prokaryotic organisms which were created during 
the project have been discarded. The eukaryotic cell lines modified by retroviral transduction are stored at -
80°C in the laboratory of the Institute for Human Genetics of the Philipps-University Marburg in Marburg. 
. 
 
Appendix III: Abbreviations 
 
aa Amino acids 
ab Antibody 
ABL1 Abelson murine leukemia viral oncogene homolog 1 
ALL Acute lymphoblastic leukemia 
AML Acute myeloblastic leukemia 
Ara-C Cytosine arabinoside 
ARG Abl-related gene kinase 
ATP Adenosine triphosphate 
B-ALL B-cell acute lymphoblastic leukemia 
Bcl-xl B-cell lymphoma-extra large protein 
BCR Breakpoint cluster region protein 
bp Base pairs 
CC (protein domain) Coiled-coil (dimerisation) domain 
CCND2 Cyclin D2 
CDK Cyclin-dependent kinase 
cDNA Complementary DNA 
CLL Chronic lymphocytic leukemia 
CML Chronic myelogenous leukemia 
DNA Deoxyribonucleic acid 
EGF Epidermal growth factor 
EPO Erythropoietin 
erbB2 Avian erythroblastosis oncogene B (see HER2) 
ET Essential thrombocythemia 
ETV6 Ets variant gene 6 
FISH Fluorescent In situ hybridization 
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GFP Green fluorescent protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
Hb Haemoglobin 
HER2 Human epidermal growth factor receptor 2 (see erbB2) 
i.e Id est  (Lat.: “ That is”) 
IFN α/β/γ Interferon α/β/γ 
IL Interleukin 
JAK Janus kinase 
JH1 (protein domain) Janus homology 1 domain 
kb Kilobases 
kD Kilodalton 
Kit Mast/stem cell growth factor receptor (SCFR)/ tyrosine-protein kinase Kit 
LAP Leukocyte alkaline phosphatase 
LDH Lactate dehydrogenase 
MD Myeloproliferative disease 
MDS Myelodysplastic syndrome 
MPN Myeloproliferative neoplasm 
NF-E2 Erythroid cell-specific nuclear factor 2 
Pax-5 Paired box protein 5 
PCM1 Pericentriolar material 1 protein 
PCR Polymerase chain reaction 
PDGFR Platelet-derived growth factor receptor 
Ph+/- Philadelphia chromosome positive/negative 
Pim-1 Proto-oncogene serine/threonine-protein kinase 1  
PMF Primary myelofibrosis 
PV Polycythemia vera 
RKI Robert Koch Institute 
RT-PCR Reverse transcription polymerase chain reaction 
RPN1 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 
RUNX1 Runt-related transcription factor 1 
SSBP2 Single-stranded DNA-binding protein 2 
STAT Signal Transducer and Activator of Transcription 
T-ALL T-cell acute lymphoblastic leukemia 
TKI Tyrosine kinase inhibitor 
VCM Viral conditioned medium 
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